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ABSTRACT
Our DNA is constantly under the assault of DNA damaging agents that are ubiquitous in
nature and unavoidable. Fortunately, our cells have evolved DNA repair mechanisms to
maintain genomic integrity against this constant attack. An important type of DNA
damage is alkylation damage, which has been the focus of this thesis, the major goal of
which is to explore the biological role of a set of alkylation repair proteins, the E. coli
AlkB and two human AlkB homologs (ABH2 and ABH3), and how they relate to the 3-
methyladenine DNA glycosylase (AAG). AAG is a base excision repair (BER) protein
that has been well-studied and is known to be involved in the repair of a wide variety of
substrates. On the other hand, the direct reversal protein AlkB, and its human homologs,
have not been so extensively characterized, but it is known that they can repair not only
DNA, but also RNA. Although there are eight human AlkB homologs, attention was
focused on ABH2 and ABH3 since they are the more well-characterized homologs and
recently implicated in DNA repair.
In order to investigate the role of the AlkB proteins, particularly in mammalian cells, I
expressed ABH2 and ABH3 in established human cell lines and investigated whether
their expression would enhance cell survival after alkylation treatment. However, no
detectable phenotype was observed in the cell lines upon treatment with the alkylating
agent methyl methanesulfonate (MMS). This is possibly due to endogenous ABH levels
being sufficient for repair. We therefore turned to characterization of the Abh2 and Abh3
null mice, as compared to wildtype and to another alkylation repair deficient animal, Aag
null mice. In addition to the primary substrates 1-methyladenine and 3-methylcytosine,
AlkB, ABH2, and ABH3 can also repair an important class of damage, the etheno base
DNA lesions, which can also be repaired by AAG. Here we have shown in a mouse
model that Abh2 and Abh3 overlap with Aag in protecting mice from sensitivity in
response to chemically induced chronic inflammation, in which etheno base lesions are
readily generated. In addition, we also employed a biochemical approach using a
comprehensive library of lesion-containing DNA oligonucleotides to study the
redundancy in repair activity between AAG and AlkB. In doing so, we have found new
substrates for AAG and in particular, 1-methylguanine, is a new substrate shared between
AAG and AlkB. Thus, although these two proteins employ different mechanisms for
repair, our studies established further evidence of the interplay between these proteins
and the different repair pathways they represent, underscoring the importance of
alkylation damage repair for proper cell homeostasis.
Thesis Supervisor: Leona D. Samson
Title: Professor of Biological Engineering and Biology
Thesis Supervisor: Linda G. Griffith
Title: Professor of Biological and Mechanical Engineering
1. CHAPTER 1 - Introduction and Background
1.1. Types of DNA damaging agents and significance
Alkylating agents are frequently found both endogenously and in our exogenous
environment and are commonly used in chemotherapy to treat cancer patients. Because
of their clastogenic and cytotoxic effects on tumor cells, they are extremely potent as
chemotherapeutic drugs. DNA damage from endogenous sources, mainly spontaneous
depurination, oxidation, alkylation, and deamination of bases, leads to about 20,000
lesions per day per cell (1).
Alkylating agents can attack DNA at 0- and N- atoms in the nucleotide bases and 0-
atoms in the phosphodiester bonds and can be divided into SN1 and SN2 agents. Both N
and O alkylations are frequently produced by SN1 agents while SN2 agents mainly
introduce alkyl adducts at the N positions (2). Different alkylation patterns result
depending on the alkylating agent, position in the DNA or RNA, and whether the DNA is
single- or double-stranded. Monofunctional alkylating agents have one reactive alkyl
group that interacts with single nucleophilic centers in DNA whereas bifunctional agents
have reactive groups that can interact with two sites. These agents usually attack DNA
by simple methylation or more complicated alkylation that can go on to cause crosslink
formation (3).
1.2. DNA Repair by different mechanisms
Exogenous and endogenous agents are always present to damage DNA and thus, cells
have developed several repair mechanisms to protect themselves.
The major DNA repair mechanisms include:
(i) direct reversal of DNA damage
a. photoreactivation
b. 0 6-methylguanine methyltransferase (MGMT)
c. oxidative demethylation
(ii) excision repair
a. base excision repair
b. nucleotide excision repair
c. mismatch repair
(iii) tolerance/avoidance
a. translesion DNA synthesis
b. DNA recombination
(iv) DNA double-strand break repair
a. homologous recombination
b. non-homologous end joining
Excision repair, tolerance/avoidance, and double-strand break repair are multi-step
pathways whereas direct reversal of DNA damage, particularly repair by the MGMT and
AlkB proteins, involves one step only. Two of the direct reversal repair mechanisms and
base excision repair are discussed in the following sections.
1.2.1. Direct reversal of base damage
The simplest form of DNA repair is the direct reversal of damaged bases to normal bases.
Mechanisms can involve direct acceptance of the alkyl group to a protein's active site or
catalytic demethylation. Direct repair proteins may act alone or involve cofactors and
cosubstrates. The 0 6-methylguanine methyltransferase (MGMT) and E. coli AlkB and
the human AlkB homologs (hABH), fall under this class and will be discussed in more
detail in later sections.
1.2.2. Base excision repair (BER)
The base excision repair (BER) pathway involves multiple proteins and is quite complex.
Single base aberrations or modification by oxidation or alkylation, sites of base loss and
strand breaks from chemical attack can be repaired by BER. First, an inappropriate base
is removed by a DNA glycosylase; the glycosylase binds to a target base and cleaves the
glycosylic bond, leaving an abasic site behind. The abasic site is then recognized by an
AP endonuclease that cleaves the phosphodiester bond 5' to the lesion to produce a strand
break with a 3' OH and a 5' abasic end. Then short-patch BER utilizes a 5'-deoxyribo-
phosphodiesterase (dRpase) DNA to remove the 5' abasic site and Pol3 fills in the single
nucleotide gap. DNA ligase I or III seals the nick. Long-patch BER replaces more than
one nucleotide and is divided into two paths, both involve PCNA, one Polp-directed and
the other Pol6/ -directed. The type of repair pathways used depends on the substrate to
be repaired and perhaps the cell type. See Figure 1-1 below for a general scheme of BER
(4).
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In E. coli, there are two 3MeA DNA glycosylases, the inducible AlkA and the
constitutively expressed Tag proteins. Tag and AlkA recognize 3MeA and 3MeG but
AlkA also recognizes deamination product of adenine, ring opened purines, some
oxidation products like etheno-adducts and also 0 2-alkylated pyrimidines (4-6). The
human 3MeA DNA glycosylase (AAG) differs from AlkA and Tag at both the sequence
and structural level, but it recognizes a wide variety of substrates as does AlkA, with the
exception of 0 2-alkylated pyrimidines (7).
DNA glycosylases act by cleaving the N-glycosylic bond between the damaged base and
the deoxyribose sugar to give an abasic site, initiating the base excision repair pathway
(see Figure 1-1). One of the main DNA repair genes being extensively investigated in the
Samson lab is the 3MeA DNA glycosylase (AAG/Aag), which recognizes a wide range
of damaged DNA bases in human and mouse cells, respectively. The release of
structurally diverse substrates appears to depend on the weakening of the glycosylic bond
(8). Base removal by AAG requires that the damaged nucleotide be flipped out from the
interior of the helix into the catalytic cavity. Binding and release of the base depends on
the shape of the base, hydrogen bonding characteristics, aromaticity and salt bridging
between the enzyme and flanking phosphates in DNA (9). A water molecule is
positioned and deprotonated by Glu125 and the nucleophile attacks the glycosylic bond
(9).
AAG is needed at an appropriate level to protect cells from the toxicity, clastogenicity,
and mutagenicity of alkylating agents. AAG, at appropriate levels, can remove 3MeA
that left unrepaired replication block that is toxic to the cell. The biological
consequences of modulating the activity of AAG are not always predictable (10).
Previous studies have shown that increased expression of AAG in many cases did not
protect but rather sensitized cells to mutagenic effects or cell death. Inappropriate AAG
expression, which can create an imbalance in BER enzymes expression, can cause
accumulation of BER intermediates downstream of the AAG in the form of abasic sites
or single-strand breaks that may be more lethal than unrepaired alkyl base lesions (4).
The resistance or sensitization by AAG (Aag in mice) to the damage induced by
alkylating agents is tissue-specific. For example, Aag-deficient mouse bone marrow cells
have increased resistance to methyl methanesulfonate (MMS) and methyl lexitropsin
(MeLex) compared to wild-type bone marrow cells (10). On the other hand, Aag null
mouse embroyonic stem cells are sensitive to MMS and MeLex, and also to BCNU and
to mitomycin C (11). Such complicated effects make the BER enzymes less attractive for
straightforward therapy.
Common alkylating agents such as mitomycin-C (MMC), carmustine (BCNU),
chloronitrosourea (CNU), and the nitrogen mustards can induce mono-alkyl adducts that
go on to cause DNA interstrand cross-links; such crosslinks prevent strand separation
during DNA replication and interfere with chromosome segregation. AAG may relieve
this toxicity by repairing the mono-alkyl lesions that lead to these interstrand cross-links
(4).
1.3.2. 06 -Methylguanine DNA Repair Methyltransferase (MGMT)
0 6-methylguanine DNA repair methyltransferase (MGMT), or more generally 0 6
alkylguanine DNA alkyltransferase, is a direct reversal repair protein that transfers the
methyl (or alkyl) group from the 0 6 position of guanine (and to a much smaller extent,
from the 04 position of thymine) to a cysteine residue in its active site; methyltransfer
inactivates MGMT in the stoichiometric repair process (Figure 1-2a). In E. coli, there are
two genes encoding DNA repair methyltransferases, the constitutively expressed ogt (12)
and the inducible ada of the Ada regulon. Both Ada and Ogt repair 06MeG and O4MeT
while Ada also repairs alkylphosphotriesters. Mammalian MGMT does not repair
04MeT very efficiently and does not repair methyl phosphotriesters. MGMT not only
removes methyl groups but also ethyl-, n-propyl-, n-butyl- and 2-chloroethyl from the 0 6
position of guanine (7).
a.
O-CH2CH2C . 0
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Figure 1-2 a. Chloroethyl adduct removal by MGMT; b. Unrepaired chloroethyl adduct results in
interstrand G-C crosslink (Adopted from ref (13))
06-alkylG and O4-alkylT lesions can be produced by a wide range of monofunctional and
bifunctional alkylating agents including BCNU, cyclophosphamide, dacarbazine,
lomustine (CCNU), procarbazine, streptozocin, and temozolomide (14), all of which are
used in the cancer clinic of chemotherapy.
used in the cancer clinic of chemotherapy.
Alkyl lesions induced by chemotherapeutic agents and cell death
The MGMT protein repairs 0 6-alkyl lesions, which can be produced by two classes of
alkylating agents, the chloroethylating agents and simple methylating agents.
Chloroethylating agents attack the 06 position of guanine to produce a base lesion that
can go on to cause an interstrand crosslink between that guanine and the cytosine on the
opposite strand as shown in Figure 1-2b. If such G-C crosslinks do not get repaired
efficiently, DNA replication can stall and single- and double-strand breaks can form.
These lesions can be toxic enough to cause cell death. However, if the 06-
chloroethylguanine lesion is repaired by MGMT, crosslink formation is prevented and
toxicity avoided (Figure 1-2a).
The protein inactivates itself during the repair process and acts independently of other
proteins. MGMT binds DNA and scans for 06 alkylation (15). The hydrophobic active
site accepts the alkyl group and hydrogen-bonds with side-chain residues next to the
acceptor Cys145 (16). The alkylated inactivated MGMT falls off the DNA quickly and
is degraded very rapidly relative to the unalkylated protein (17).
Methylating agents, such as procarbazine, temozolomide, streptozotocin, and dacarbazine,
are the second class of alkylating agents that produce 06 alkyl lesions disrupting
hydrogen bonding to cytosine but does not cause much distortion. This results in
06MeG:T mispairs, ultimately leading to a point mutation of G to A. The toxicity of
these lesions comes from initiation of mismatch repair. Since mismatch repair targets the
newly synthesized strand, the original 06-MeG will not get repaired. A thymine will be
incorporated opposite to the 06-MeG and mismatch repair will again recognize and
excise the T, leading to iterative and futile repair of the daughter strand (futile cycling).
Although 0 6-MeG lesions are not as cytotoxic as the interstrand crosslinks induced by
chloroethylating agents, the DNA strand breaks from futile mismatch repair can induce
apoptosis (18). Cells and tissues express MGMT at different levels (19-21).
Overexpression of MGMT in transgenic mice protects against thymic lymphomas
induced by methyl nitrosourea (MNU) (22) whereas Mgmt-knockout mice are
exceedingly sensitive and develop many lymphomas (23, 24).
06 -BG-resistant mutant MGMT
The irreversible inactivation of MGMT upon covalent transfer of the adduct allows any
substrate for the protein to be an irreversible inhibitor of MGMT. This has actually been
exploited in chemotherapy to increase a tumor's sensitivity to alkylating agents, of which
0 6-benzylguanine (06-BG) is a candidate. MGMT can be inhibited by 0 6 -BG, which is
used frequently in combination with alkylating agents that produce 0 6-MeG to treat solid
tumors such as brain tumor, where the endogenous MGMT level is high. The inhibitor
0 6-BG inhibits MGMT by the transfer of the benzyl group to the active site cysteine
residue of the MGMT protein (25).
1.3.3. AlkB/human AlkB Homologs (hABH)
The E. coli alkB gene was discovered as early as 1983, 25 years ago, with the isolation of
alkB mutants specifically sensitive to the SN2-type methylating agent MMS but not to
SN1 alkylating agents (26). E. coli AlkB was also shown to give the same kind of
alkylation resistance in human cell lines, as in E. coli cells (27). However, the human
AlkB homolog (hABH) proteins have only been shown in recent years to give E. coli
cells alkylation resistance, repairing DNA and/or RNA. These proteins have also been a
main subject of exploration due to its simple direct repair capability. Sequence alignment
showed that the iron-binding and 2-oxoglutarate-binding sites are conserved in the
bacterial and the human proteins. In fact, AlkB and its human homologs belong to the 2-
oxoglutarate/Fe oxygenase superfamily. These proteins (AlkB, ABH2, and ABH3) are
involved in catalyzing oxidative demethylation reactions directly reverting damage
primarily reverting 1MeA and 3MeC to A and C, respectively (28, 29).
Repair mechanism and preferred substrates
AlkB differs from many other DNA repair proteins in that it depends on unexpected
cofactors for activity. In a bioinformatics study by Aravind and Koonin in 2001, AlkB
was identified as a member of the superfamily of dioxygenases that require oxygen, 2-
oxoglutarate and iron as cofactors (30). Based on these findings, two independent studies
later showed that AlkB is an oxidative demethylase removing methyl groups from 1-
methyladenine and 3-methylcytosine from DNA (31, 32). The crystal structure of the
AlkB-dsDNA complex reveals an active site where the damaged base (1MeA) is flipped
into the active site with the two bases flanking the damage squeezed together, distorting
the lesion-containing strand (33).
AlkB repairs lesions in the presence of oxygen, Fe2+ (a cofactor) and 2-oxoglutarate (or
(X-ketoglutarate, as a cosubstrate). The methyl group from the methylated substrate is
first oxidized to a hydroxymethyl group and then released as formaldehyde. Oxygen is
consumed during the reaction and 2-oxoglutarate is converted to succinate and CO 2.
AlkB can act alone, independent of other proteins (34).
o O
"NH, OIO 
- 1  NH, NH,
CH+ N 2-Oxoglutarate Succinate N
Succinat
DNA
(RNA)
1-Methyladenine
DNA
(RNA)
HCHO
DNA
(RNA)
Adenine
Figure 1-3 AIkB repair mechanism of 1meA (From ref (35))
SN2 type alkylating agents (such as MMS, DMS, and Mel) produce more IMeA and
3MeC lesions in single-stranded DNA than SNI agents (31). Most DNA lesions are
induced in double-stranded and single-stranded DNA to similar extents by alkylating
agents; however, AlkB substrates are preferentially formed in ss-DNA (36). The
preferred substrates are ss- and ds- DNA and ssRNA for AlkB (28).
IMeA and 3MeC are only induced by alkylating agents in low amounts in double-
stranded DNA but AlkB can efficiently remove them from both ds- and ss- DNA in vitro
(31, 32). In vivo, AlkB may be involved in repairing lesions from transiently single-
stranded regions as indicated by its ssDNA repair capacity (during replication and
transcription) and in repairing dsDNA in general (34). 1MeA and 3MeC are primarily
found in single strands because in duplex DNA, the N site in adenine and N3 in cytosine
(methylation sites) are involved in base pairing and hence are relatively protected from
SII I.1,
LkN
methylation in double-stranded DNA. Since the AlkB substrates are usually found in
single strands and a large amount of RNA in the cell is single-stranded, it would make
sense that many of the 1MeA and 3MeC would be in RNA instead of DNA. Therefore,
the cell may possibly also have a need for RNA repair (34).
In addition to the 1MeA and 3MeC lesions, AlkB has been shown to repair 1-
methylguanine (1MeG) (37, 38), 3-methylthymine (3MeT) (37-39), and 3-ethylcytosine
(37), although with weaker activity on 1MeG and 3MeT than on 1MeA and 3MeC. It
was later shown that AlkB substrates also include exocyclic lesions such as 1,N6-
ethanoadenine (EA) (40), 1,N6-ethenoadenine (EA) (41, 42) and 3,N4-ethenocytosine (EC)
(41). Etheno adducts are generated by reaction of DNA with lipid oxidation products and
also with metabolites of carcinogen in the environment such as chloroacetaldehyde.
Etheno lesions have indeed been shown to be repaired efficiently by DNA glycosylases
in mammalian, yeast, and bacterial cells (43-45).
Mammalian AlkB homologs
In mammals, there appear to be eight different AlkB homologs based on protein sequence
similarity (46, 47), hABH1-8 in humans (or mAbhl-8 in mice). hABH1 was the
homolog first identified and has the most protein sequence similarity with E. coli AlkB.
ABH1 was shown to be partially active in the complementation of alkB-deficient E. coli
upon treatment with MMS (48) although this result was not reproducible in more recent
studies (28, 29). However, ABH1 has now been shown to demethylate 3MeC (49), and
as mentioned before, ABH2 and ABH3 were found to demethylate lmeA and 3meC in
DNA and/or RNA (28, 29). For the human homologs, only hABH1, hABH2, and
hABH3 have been shown to have repair activity on DNA and also RNA (28, 31, 49-51).
mAbh2 displays in vivo and in vitro repair activity on FA (52) and in vitro activity against
EA has been shown for hABH3 (42). Similar to AlkB, ABH2 and ABH3 also can act
independent of other proteins during the repair process (Figure 1-3).
In a study by Tsujikawa et al., the human ABH1-ABH8 gene transcripts were detected
throughout 16 human tissues examined (53). In agreement with previous studies showing
localization of ABH2 and ABH3 (28), Tsujikawa et al. showed in a comprehensive study
that ABH1, ABH3, ABH4, ABH5, ABH6, and ABH7 are expressed in both the
cytoplasm and the nucleus and that the full-length hABH2 is in the nucleus (53). For
hABH5 transfected into HeLa cells, the protein also shows a dot-like pattern in the
cytoplasm. The full-length hABH8 newly cloned from testis cDNA that contains the
20G-Fe(II) oxygenase domain, an RNA-binding motif, and a methyl-transferase domain,
was localized exclusively in the cytoplasm in transfected HeLa cells (53).
The preferred substrates are ds-DNA for hABH2, and ss-DNA and ss-RNA for hABH3
(28). Aas et al. have experimentally shown that in E. coli, AlkB and hABH2 repair both
ss- and ds-DNA significantly whereas hABH3 shows modest repair of ssDNA and
insignificant in dsDNA. Furthermore, AlkB and hABH3 repair ssRNA but hABH2 does
not (28). It appears that hABH2 and hABH3 complement each other and that together
they have the activity of the E. coli AlkB protein. The crylstal structure of ABH2-
dsDNA shows that no significant distortion is necessary since the intercalating finger
Phel02 fills the space vacated by the flipped out base (33).
Table 1-1: Repair preference of AlkB, hABH2, and hABH3
Significance of RNA repair and in vivo repair by ABH2/ABH3
It is likely that RNA methylation damage needs to be repaired to prevent the production
of faulty proteins by translation of damaged mRNA, by charged tRNA and damaged
ribosomes. However, it remains unknown how the cell distinguishes between RNA
alkylation damage and naturally occurring RNA post-transcriptional modifications that
are crucial for proper translation. Although RNA methylation damage has not been
thoroughly studied, it is known that 1MeA modification in ribosomal RNA can have
detrimental effects on binding of the codon-anticodon complex (54) and on reverse
transcription (55). Translation may be affected since the modified bases are involved in
direct base-pairing (28).
From Northern hybridization studies by Duncan et al., hABH2 mRNA levels are highest
in liver and bladder while hABH3 mRNA levels are highest in spleen, prostate, bladder,
and colon tissues (29). For carcinoma cell lines, HeLa cells show high hABH2 mRNA
and very low hABH3 mRNA levels, which is also almost absent in two of the Burkitt's
lymphomas cell lines (29). Furthermore, using mice deficient in Abh2 and/or Abh3,
1MeA lesions were shown to accumulate significantly in the genome of mice deficient in
mAbh2 during aging, indicating that mAbh2 is important in repairing such lesions
induced by endogenous methylating sources (35, 56). However, mAbh3-deficient cells
and extracts showed no repair defect of the lesions, although purified hABH3 shows
repair activity in vitro. The repair of IMeA and 3MeC by wildtype and mAbh3-deficient
mice was very similar (56).
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2. CHAPTER 2--AlkB/ABH Expression and Repair Activity in Bacterial
and Mammalian Cells
2.1. Introduction
MGMT is an example of a direct DNA repair protein shown to render many cells and
organisms alkylation resistant in previous studies and is being tested in combination with
the 0 6-BG inhibitor drug to treat solid tumors in clinical trials (1). It therefore seemed
worthwhile to study other direct reversal proteins to determine whether they have the
potential for DNA repair in human cells as shown to be true for MGMT. Because the E.
coli AlkB protein gives alkylation resistance in both E. coli and HeLa cells (2), we
hypothesized that the same could be done with the human AlkB homologs (hABH),
another set of proteins involved in the direct reversal of damage in DNA, and in addition
RNA (3). Early work of this thesis was aimed at determining whether human ABH1,
ABH2, and ABH3 expression can confer alkylation resistance in human cells.
2.2. Materials and Methods
2.2.1. Construction of bacterial and mammalian expression vectors containing
hABH1, hABH2, or hABH3
Our goal was to express hABH1, hABH2, and hABH3 in human cells. The cDNA
fragments encoding the proteins were PCR-amplified from existing vector constructs
generated by Thomas Begley in the Samson laboratory (unpublished). To monitor
expression of the protein, a hemagglutin (HA) tag was added to either the 5' or 3' end of
the gene so that an anti-HA antibody could be used in Western blot analysis. Constructs
without an HA tag were also constructed in case the fused tag interfered with the normal
function of the gene product (Figure 2-1).
The vectors used included bacterial expression construct (pET-DEST42 (Invitrogen) for
validation of AlkB, ABH1-3 function by MMS gradient plate assay) and mammalian
constructs--pMMP-f2-IRES-GFP, p500 (episomal), pCDNA3.2/V5-DEST (constitutive)
and pLenti/TO/Puro-DEST (lentiviral, tetracycline-regulated expression system; Eric
Campeau, Cooper Lab, LBNL)).
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HA aIkB
at kB IHA
hABH1
HA hABH1
hABH1 HA
hABH2
HA hABH2
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Figure 2-1: Structure of the HA-tagged and untagged hABH constructs
2.2.2. Mammalian expression
Transfection of cell lines
The pMMP-f2-IRES-GFP-alkB/hABH and pcDNA3.2N5-DEST-alkB/hABH plasmids
were transfected into target cells using the lipofectamine transfection reagent (Invitrogen).
Selection of individual clones was performed over a two-week period and expansion of
the stable clones over another week. This ensured that the insertion into the genome was
stable and not transient. During the cloning and expansion processes, the pMMP-f2-
IRES-GFP-alkB/hABH and the pcDNA3.2/V5-DEST-alkB/hABH clones expressed GFP
or were geneticin-resistant, respectively, indicating the presence of the plasmids in the
cells. Stable clones were then frozen down and harvested for further analysis.
Confirmation -- In vitro transcription and translation
In vitro transcription and translation was done using the alkB/hABH-containing vectors
with a T7 RNA polymerase region. After transcription, the transcription product was
used in translation using rabbit reticulocyte lysate with 35S-labeled methionine. The
labeled protein products translated from the mRNA transcripts of alkB/hABH HA were
then detected by SDS-PAGE analysis followed by phosphorimaging. Western blot
analysis was also performed to detect the HA-tagged proteins once the labeled bands
were seen by phosphorimaging.
2.2.3. MMS gradient assay
Expression constructs containing alkB, hABH1, hABH2, and hABH3 cDNAs, with either
no tag, 5'-HA tag, or 3'-HA tag, were transformed into wild-type and alkB-deficient E.
coli strains. The strains used were HK81(DE3)(wild-type) and HK82(DE3) (alkB-
deficient). A gradient of MMS (an SN2 alkylating agent) was generated across an agar
plate containing ImM IPTG (to induce protein expression) and the appropriate antibiotic.
Cultures of HK81(DE3) and HK82(DE3) containing all the different bacterial expression
constructs, along with the empty vector as negative controls, were spread across the
gradient. The sensitive phenotype can be seen when the strain dies off whereas resistant
strains would survive across most of the plate.
2.2.4. Colony forming survival assay
Cell lines transfected with AlkB/ABH expression vectors were tested for MMS
sensitivity using a colony forming survival assay. Stable or transiently transfected cells
were both used. To perform the survival assays, cells were treated for 1 hour in O1mL
serum-free media with different doses of MMS. After 1 hour of treatment, the media was
changed to complete media with serum and the cells were diluted and plated at 500, 5000,
or 50000 cells/plate and allowed to grow for 10-14 days for colony formation.
2.2.5. Ex vivo bone marrow survival assay
Abh2 and Abh3 knockout mice made by Arne Klungland's group from Norway (4) were
made available to us. Bone marrow survival experiments using the wild-type and Abh2,
Abh3, and Abh2/Abh3 double-mutant mice were performed to test whether Abh2 and/or
Abh3 were important in protecting bone marrow from alkylation damage. The femurs
were taken from the mice and crushed to extract the bone marrow cells. MMS treatments
immediately followed and the bone marrow cells were then resuspended in methocult to
allow colony formation of myeloid lineage cells (5). Cell colonies were counted after
nine days.
2.3. Results
2.3.1. MMS gradient plate assay showed AlkB/ABH activity and no interference
from HA tags & detection of HA-tagged AlkB/hABH expression
It was important to ensure that the bacterial expression constructs containing hABH1,
hABH2, and hABH3, each with no tag, 5'-HA, and 3'-HA, were functional. Thus, after
transforming into wild-type (HK81(DE3)) and alkB-deficient (HK82(DE3)) E. coli
strains, the MMS gradient plate assay was performed to observe whether the expression
of AlkB/ABH in E. coli can confer resistance upon alkylation damage. Figure 2-2 shows
a representative MMS gradient plate with E. coli containing the bacterial expression
constructs of AlkB/ABH. Results show that AlkB gave full resistance, hABH I modest
resistance, hABH2 full resistance, and hABH3 little to modest resistance. The HA tags
did not appear to interfere with the protein functions since similar activity was observed
in the presence or absence of the HA tag, and whether the tag was placed at 5' or 3' end
made no difference (results not shown).
0% 0.045% MMS
Wild-type / empty vector
AIkB deficient / empty vector
AlkB deficient / p500-DESTA-alkB
AIkB deficient / p500-DESTA-hABH1 5'HA NM
AIkB deficient / p500-DESTA-hABH2 3' HA
AIkB deficient / p500-DESTA-hABH3 5'HA
AlkB deficient / p500-DESTA-hABH1 5'HA XM
Figure 2-2: MMS gradient plate of p500 -AlkB/hABH HA in AlkB-deficient E. coli
The anti-HA antibody (Abcam) was used to detect expression of the HA-tagged
constructs in both the E. coli. Figure 2-3 shows a Western blot showing expression of the
HA-tagged proteins in E. coli.
33-35 kDa
23-25 kDa
1 2 3 4
Figure 2-3: Western blot with showing AlkB/ABH expression in E. coli
2.3.2. In vitro transcription and translation
In order to confirm whether the AlkB/ABH constructs can indeed support transcription
and translation, in vitro transcription and translation was done using the alkB/hABH-
containing vectors with a T7 RNA polymerase region. After transcription, the
transcription product was used in translation using rabbit reticulocyte lysate with 35S-
labeled methionine. The labeled protein products translated from the mRNA transcripts
of alkB/hABH HA were then detected by SDS-PAGE analysis followed by
phosphorimaging. Western blot analysis was also performed to detect the HA-tagged
proteins once the labeled bands were seen by phosphorimaging.
Radiolabeled bands at the expected product sizes were seen (Figure 2-4), except for
ABH2, but somehow could not be detected by Western (data not shown), even with
Lane assignments:
1. ladder
2. E. coli AlkB 5'HA
3. E. coli hABH2 3'HA
4. E. coli hABH3 3'HA
different anti-HA antibodies. However, based on the fact that the bands on the exposed
gel from in vitro translation were clean and distinct, it was worthwhile to check for
protein functions anyway even if the HA tag could not be detected.
< < < < < <
33-35 kDa
23-25 kDa
Figure 2-4: in vitro translation products from phosphorimaging
(Note: for hABH3 5'HA, the band is too faint to see clearly.)
2.3.3. Mammalian expression and survival assays in human cell lines
Protein expression detection had been problematic in stable populations of human cells,
such as K562 and HeLa. It was thought that perhaps long-term growth selects against
high level expression of ABH proteins. Hence, HEK293T cells were transiently
transfected to see if the proteins could at least be expressed transiently. HEK293T cells
are human embryonic kidney cells and are known to allow high transfection efficiency.
Cells were harvested 3, 6, and 10 days post-infection. Extracts were prepared for
Western blot analysis and growth inhibition assay carried out. Western blots with HA
antibody detected AlkB 3'HA in transiently transfected HEK293T cells. (Note that this
was the first time that HA-tagged AlkB/hABH proteins were detected in cell extracts.)
They were only detected in transiently transfected HEK293T cells and not in stable
transfectants, as illustrated with the Western blot below in Figure 2-5.
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Figure 2-5: Western blot showing AlkB 3'HA in 293T cells 3-, 6-, and 10-day post transfection
After observing the expression of AlkB protein in the transiently transfected HEK293T cells,
survival assays were performed. Figure 2-6 shows results from a representative experiment
using MMS. Multiple attempts of the assays with different cell lines (such as K562 and HeLa)
with different transfection status (transient or stable) showed similar results: the differences in
the survival of cell lines transfected with empty vector versus the AlkB/ABH constructs were
very small and not statistically significant.
Survival Assay for 3-day transient 293T pcDNA3.2/V5-DEST-
alkBIhABH HA 4-day post treatment
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Figure 2-6: MMS survival assay with 3-day transient 293T pcDNA3.2N/V5-DEST-alkB/hABH HA 4 days after
treatment
2.3.4. Survival in Abh knockout models
To determine the significance of ABH-related repair in mammalian cells, it would be
important to check for any sensitivity to damage in ABH-knockout cells compared to
wild-type cells. Mouse bone marrow cells were treated with MMS and methyl
nitrosourea (MNU), a SN2 and a SN1 alkylating agent, respectively. Ex vivo bone marrow
treatment results with MNU (as negative control) are shown below in comparison with
those with MMS (Figure 2-7).
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Figure 2-7: Ex vivo bone marrow treatment results with MMS and MNU
As seen from above, bone marrow cells from the Abh2-/-Abh3 / - double mutant mice were
significantly more sensitive than wild-type cells to MMS damage. Abh3-- bone marrow
cells were not sensitive and Abh2-/- cells were as sensitive as those of the Abh2-'-Abh3 -'
to MMS damage. This shows that a deficiency in Abh2 alone (but not Abh3 alone) can
cause sensitivity to MMS in the bone marrow. This finding was consistent with that
shown by Ringvoll et al (4) in mouse embryonic fibroblasts (MEFs) from the Abh2- -and
1
m
0
Abh3 - - mice. However, the double mutant bone marrow cells were not more sensitive
than wild-type against MNU damage. This was within expectation that the AlkB proteins
would repair damage induced by SN2 and not SN1 alkylating agents, consistent with the
findings by Chen et al (2). Hence, we saw that Abh2, and not Abh3, appeared to have a
protective role against the SN2 alkylating agent MMS in mouse bone marrow.
2.4. Discussion and summary of chapter
Bacterial expression constructs carrying E. coli AlkB and its human homologs were built
and sequence verified and protein expression also checked. Subsequently, the expressed
proteins were shown to be active as judged by their ability to confer MMS resistance as
determined in vivo in bacteria on MMS gradient plates. AlkB restored AlkB-deficient E.
coli strain to wild-type phenotype. Among the human homologs hABH1, hABH2, and
hABH3, hABH2 conferred rescue, similar to AlkB levels, while hABH3 and hABH1
showed partial rescue.
In order to verify whether the AlkB protein and its human homologs could confer
increased MMS resistance in mammalian cells, mammalian expression constructs were
also made. Expression was confirmed by in vitro transcription/translation and Western
blotting. Numerous attempts to detect increased survival of the human cell lines upon
MMS exposure with the different vectors and different cell lines failed. Possible
explanations for the failure of transfected AlkB/ABH expression constructs to confer
MMS resistance are that the expressed proteins might not be active in the human cells, or
that the endogenous hABH activity was already sufficient to rescue the cells from MMS
damage. Furthermore, repair by AlkB/hABH generates toxic formaldehyde and it may be
more beneficial to the cells to avoid having the excess formaldehyde byproduct than to
have the DNA lesions repaired by the expressed AlkB/hABH. Maintaining the expressed
AlkB/hABH proteins could be a burden to the cells. It is also possible that the ABH
proteins may need to be in a complex in order to be fully functional, and that the other
components of the putative complex were limiting.
However, with Abh2 and Abh3 knockout mouse bone marrow, Abh2 appears to play the
major role in rescuing the cells from MMS-induced toxicity. This finding was very
encouraging and was the first demonstration that Abh2 protects bone marrow against
alkylation induced toxicity. It would therefore be interesting to investigate whether Abh2
and/or Abh3 rescue other mouse cell type from alkylation induced toxicity.
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3. CHAPTER 3 - Chronic inflammation study on animals deficient in
Abh2, Abh3, and Aag
3.1. Introduction
Chronic inflammation has been linked to increased cancer risk. One example of such a
link is the increased risk of colorectal cancer in patients with inflammatory bowel disease
(IBD). One million people per year are affected with IBD which includes ulcerative
colitis (UC) and Crohn's disease (1). IBD patients have damage to the epithelial layer of
the gastrointestinal tract, which serves as a barrier against potentially harmful agents such
as acid, enzymes, bacteria, and toxins (2, 3). Patients with extended UC are 19 fold more
likely to develop colorectal cancer than the general population (4). The risk of colon
cancer in UC patients increases with the extent of the colon involvement, severity, and
duration of the disease (5). The link between cancer and inflammation is also supported
by the fact that controlling or inhibiting inflammation in IBD patients correlates with a
reduced cancer risk. Long-term use of anti-inflammatory drugs such as nonsteroidal anti-
inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 (COX2) inhibitors lowers
cancer risk significantly (6), suggesting similar molecules could be targets for cancer
treatment.
Chronic inflammation has also been correlated with increased levels of DNA base
damage in the inflamed tissue (7-9). Ulcerative colitis patients suffer episodes of active
inflammation (flare-ups) separated by periods of disease inactivity (remission). Active
inflammation activates and recruits leukocytes and tissue mast cells (10) and leukocytes
and phagocytic cells secrete proinflammatory cytokines, chemokines, growth factors, and
matrix-degrading enzymes. Furthermore, as a mechanism to fight infection,
inflammatory cells such as neutrophils and macrophages generate and release reactive
oxygen and nitrogen species (RONS) (10). However, uncontrolled inflammation can
lead to more RONS and thus, oxidation and deamination of DNA bases. In addition, base
alkylation can result indirectly via lipid peroxidation that forms a byproduct that can react
with DNA to generate etheno base lesions (11). Chronic inflammation has thus been
correlated with increased levels of EA, 1,N2-eG, EC and 8oxoG in the affected tissues (7-
9).
In a previous study in the Samson lab, it was found that the Aag 3-methyladenine DNA
glycosylase can ameliorate colon damage and decrease tumor development in response to
chronic colonic inflammation (9). Aag initiates the base excision repair (BER) pathway
for a wide range of structurally diverse damaged bases, including 3meA, EA, Hx, and
8oxoG. Aag-deficient mice showed a greater increase in oxidized (8oxoG) and etheno
DNA base damage (EA and EC) after chronic inflammation in colon tissue compared to
wildtype, and this correlated with more pronounced colon tissue damage and increased
tumor development in Aag-deficient versus wildtype mice (9). These results show that
the repair of chronic inflammation-induced DNA lesions is important for colon cancer
prevention. Another RONS-related base damage, the EC lesion in DNA, is tightly bound
by Aag but not excised (12). Thus, the higher accumulation of EC in Aag-deficient
versus WT mice (9) seems to suggest that although Aag does not directly excise EC, it
can still assist in its repair. This may be an indication that Aag serves to recruit other
repair pathway(s) to help rid the DNA of RONS-induced EC DNA lesions.
AlkB (and its mammalian homologs) may be one such alternative pathway since it
repairs cyclic etheno lesions such as FA and cC via direct reversal (13), in addition to
repairing simple alkylated adducts such as 1-methyladenine and 3-methylcytosine (14,
15), 1-methylguanine (15, 16), 3-methylthymine (15-17), and 3-ethylcytosine (16). In
vivo and in vitro repair activity on cA (18) have been shown for mammalian ABH2 and
in vitro activity against EA has been shown for hABH3 (19). Since both Aag and AlkB
efficiently repair etheno DNA lesions, known to be induced during chronic inflammation,
we set out to determine whether Abh2 and Abh3, along with Aag, contribute to the
amelioration of the response to chronic inflammatory colitis seen in mice.
For IBD and its associated colorectal cancer (CRC), several animal models have been
developed and the most widely used involves treatment with dextran sulfate sodium
(DSS) (20). These models mimic the course of human ulcerative colitis, eventually
leading to colorectal tumors with similar pathology to those of humans. Originally
developed by Ohkusa (21) as a hamster model, the DSS model was later adapted to mice
by Okayasu et al. (20). DSS is orally administered to the mice in the drinking water,
resulting in acute and chronic colitis similar to UC. Following three to five cycles of
DSS, mice exhibit signs of colonic mucosal inflammation with ulcerations, body weight
loss, and bloody diarrhea (20). DSS is toxic to mucosal epithelial cells, which can lead to
dysfunctional mucosal barrier and mucosal inflammation (22). The mechanism by which
DSS induces colitis is not clear but it is proposed that ingestion of DSS may destroy
mucin content or alter macrophage function and cause toxicity in the epithelium, thus
increasing exposure to luminal antigens, and activating macrophage inflammatory
responses (20, 23-25). However, the mouse colitis model using DSS requires an
extended and/or repeated cycles of DSS treatment to induce colitis and colitis-related
CRC, and the incidence and multiplicity of induced tumors are relatively low (26).
Azoxymethane (AOM) is an alkylating agent commonly used in conjunction with DSS
in experimental models of colorectal cancer, in conjunction with DSS. Structurally
similar to cycasin, a natural compound that strongly induces tumors in colons and
rectums of rats and mice (27, 28), AOM induces 0 6-methylguanine adducts in DNA,
causing G-)A transition mutations and when given in multiple doses, causes the
induction of tumors in the distal colon of rodents (29). An initiating single dose of AOM
is commonly used in combination with repeated cycles of DSS. The combined treatment
enhances tumor formation because AOM acts as a tumor initiator and DSS, by mimicking
episodic UC, acts as a tumor promoter (20). However, C57BL/6 mice receiving a single
dose of AOM do not develop dysplasias/tumors/adenomas, indicating that a single-dose
of the colonic carcinogen is insufficient to induce colorectal tumors in the absence of
inflammation (9, 30).
Here, we set out to examine the effects of deficiency in the DNA repair proteins Abh2
and Abh3 and to assess their roles in tumor development. In addition, we investigated
the genetic interaction of Abh2 and Abh3 with Aag in susceptibility to chronic
inflammation. In order to assess any overlap or interaction between Aag and Abh2/3
activity, we induced chronic inflammatory colitis in single- and double-mutant mice and
monitored the phenotypic outcome. Our results show that Aag plays the major role in
ameliorating the response to chronic inflammation. Although increased sensitivity to
chronic inflammation is apparent in the Abh2'-Abh3-'- double mutant, niehter of the single
mutants showed increased sensitivity.
3.2. Materials and Methods
3.2.1. Animals
All procedures were approved by the MIT Committee on Animal Care. Abh2-- and Abh2-
'-Abh3 -' mice were in 129/SvEv background whereas Aag-'-, Aag-Abh2-', and Aag-Abh3 -
Awere in a mixed C57BL/6 and 129/SvEv 50/50 (Fl generation) background. Wild-type
(WT) mice in both genetic backgrounds: 129/SvEv and Fl mice from a C57BL/6 x
129/SvEv cross were also included as controls. All animals were 6-8 weeks old at the
beginning of experiments. The mice were given a standard diet and housed in the MIT
mouse facilities. Note: For simplicity, the strains will be referred to as 129 for 129/SvEv,
B6 for C57BL/6, and 129/B6 for the mixed background.
3.2.2. Treatments
To study the effect of chronic inflammation in the absence of Abh2 and Abh3, WT,
Abh2-'-,and Abh2'-Abh3 -- mice were given repeated cycles of DSS in the drinking water
to induce episodic colitis. To determine the consequences of a tumor initiation event
followed by chronic inflammation in the absence of Aag and/or Abh repair, WT, Abh2-'-,
Abh2-'Abh3- , Aag' -, Aag--Abh2-'-, and Aag-Abh3-' mice were treated with AOM prior
to the repeated cycles of DSS administration, for tumor initiation.
DSS only
Mice were exposed to seven cycles of DSS. Each cycle consisted of 5 days of 2.5% DSS
(MW 36,000-50,000, MP Biomedicals) in the distilled drinking water followed by 16
days of regular tap water, except for the last cycle in which DSS treatment was followed
by 4 days of regular tap water. Four days after the 7th DSS cycle, the mice were
sacrificed. Figure 3-1A illustrates this treatment scheme.
AOM+DSS
Five days before the first DSS cycle, a single dose of 12.5 mg/kg of AOM (Midwest
Research Institute, NCI Chemical Repository) was injected intraperitoneally (i.p.) to the
mice. Subsequently, five cycles of DSS were administered (as described above).
Treatment scheme is illustrated in Figure 3-1B.
3.2.3. Euthanasia and Tissue Collection
Mice were euthanized by CO 2 inhalation. The whole animal was weighed and colon and
spleen collected from each mouse. The colon (from cecum to anus) was removed from
each mouse, washed with IX PBS, cut open lengthwise and length measured.
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Figure 3-1 Two different treatment schemes were used in this study. (A) Treatment with
7 cycles of DSS (DSS alone). (B) Treatment with an initial dose of AOM followed by 5
cycles of DSS (AOM+DSS). White blocks indicate days of normal water treatment and
black blocks indicate 5 days of 2.5% DSS in the drinking water.
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Polyps/tumors were counted under a stereomicroscope (magnification, 45X). The colon
was then fixed in 10% neutral buffered formalin and transferred to 70% ethanol. The
spleens were weighed and fixed in 10% neutral buffered formalin and then transferred to
70% ethanol similar to the colon.
3.2.4. Tissue Processing and Histopathology
The collected spleens and colons in 70% ethanol were processed by the MIT Center for
Cancer Research Histology lab where they were embedded in paraffin, sectioned at 5 gm,
and Hematoxylin and Eosin (H&E) stained. The H&E stained slides were then scored by
Dr. Sureshkumar Muthupalani (Division of Comparative Medicine, MIT) for the
following: inflammation; epithelial defects; crypt atrophy; hyperplasia; dysplasia /
neoplasia; and area affected by dysplasia/neoplasia. Scoring criteria used by Dr.
Muthupalani are shown in the Chapter 3 Appendix.
3.2.5. Statistics
Statistical analyses were done using the GraphPad Prism software. Mann-Whitney test
was used to compare data on spleen weights, colon lengths, tumor multiplicities, and
pathological scoring. Survival rates on the whole animals were analyzed using Kaplan-
Meier survival curves with the Log-Rank test.
3.3. Results
For simplicity, the strains will be referred to as 129, B6, and 129/B6 for the F1 mixed
background. In addition, the following graphs showing data on the spleen weight, colon
length, tumor incidence, tumor multiplicity, and histopathological scores contain
combined data for mice that survived to the end of the treatment regime and for mice that
died during the study. The data were very similar from the two sets of mice and so were
combined for a more complete representation. Please see tables comparing disease
markers of the two sets in the Chapter 3 Appendix.
3.3.1. The 129 and B6 mice respond differently to DSS and to AOM+DSS.
We first examined the susceptibility of the wild-type mice in the 129 versus the B6
genetic backgrounds. Because double knockouts of Aag-'-Abh2 -' and Aag-'-Abh3- mice
were in a mixed 129/B6 background, the mixed background was also examined.
Interestingly, 129 and 129/B6 wild type mice displayed different susceptibility to the
treatment, as seen in the survival after an initial AOM treatment followed by 5 cycles of
DSS (AOM+DSS) (Figure 3-2A). The 129 mice exhibited a significant decrease in
survival compared to mice in the 129/B6 background (p=0.0174) and the B6 background
(p=0.0078). Wild type mice in the three strain backgrounds appeared to have similar
spleen weights relative to body weights after AOM+DSS (Figure 3-2B). However, 129
mice trended toward a higher tumor multiplicity than mice in the 129/B6 or in pure B6
(Figure 3-2C). Furthermore, 129 WT mice also showed a significantly greater decrease
in colon length (p=0.0412) than WT mice in the 129/B6 (Figure 3-2D). The greater
susceptibility of 129 versus B6 was also observed in the histopathological scores. The
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induced by AOM+DSS. (A) Kaplan-Meier survival curves for the WT mice in the different backgrounds. (B) Spleen
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scores were significantly increased for most criteria in 129 WT mice compared to B6 WT
from historical data (Figure 3-2E). These data indicate that these two genetic
backgrounds exhibit differential susceptibility to colitis and that it was necessary to use
appropriate WT controls in our experiments since the genetic background itself confers
differences in susceptibility to AOM+DSS.
3.3.2. Abh2-Abh3 /' knockout animals suffer more severe general pathologies than
WT after DSS-induced colonic inflammation.
Inflammation-induced RONS can directly oxidize and deaminate DNA bases and
indirectly alkylate bases via lipid peroxidation that leads to a byproduct that can react
with DNA to generate etheno base lesions (11). A previous study showed that nuclear
extracts lacking Abh2 lacked EA repair activity (18), indicating Abh2 is important in the
repair of this toxic and mutagenic DNA lesion. We therefore set out to determine
whether Abh2 or Abh3 proteins have protective roles in chronic inflammation. Thus, we
monitored the sensitivity of Abh-deficient mice to chronic inflammation induced by 7
cycles of DSS (DSS alone), with the treatment scheme as illustrated in Figure 3-1A.
129 WT and 129 Abh2 - - mice exhibited similar survival rates during the DSS-alone
treatment scheme as shown in Figure 3-3A. The Abh2-'Abh3-'- mice showed slightly
lower survival than the 129 WT and Abh2 -'- mice that did not reach statistical difference.
Overall, these animals did not exhibit any major differences in whole animal lethality in
response to episodic colonic inflammation.
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Figure 3-3 Abh2-/-Abh3-/- mice appear to be more susceptible than WT and Abh2-/- mice in DSS alone
treatment. (A) Kaplan-Meier survival curves for the various genotypes in the study. (B) Spleen weight as a
percentage of body weight. Data are mean ± SD. (C) Change in colon length. Data are mean ± SD. Black
bars represent historical data in C57BL/6 from previous study (11).
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We next assessed disease markers of colitis including increased spleen weight in 129 WT,
129 Abh2-'-, and 129 Abh2-' Abh3 -'- animals after DSS-induced chronic inflammation. In
colitis, blood is often lost from stools due to tumors or ulcers, leading to splenomegaly
associated with extramedullary hematopoiesis (9). Figure 3-3B shows Abh2- -Abh3-
exhibit significantly greater increase in spleen weight compared to WT (p<0.0001) and
Abh2 - (p=0.0064) animals. These increases were much larger than those observed
previously comparing B6 Aag-'- to B6 WT animals (9) (historical data, Figure 3-3B).
A decrease in colon length is commonly observed in this disease model and is attributed
to repeated healing of ulcers and fistulas (9). In addition to DNA damage, DSS can also
adversely affect protein folding in the endoplasmic reticulum (ER) and cause ER stress in
the epithelial cells of the gastrointestinal tract (20, 23-25). Such damages lead to cell
death and require more healing by the colon, giving rise to a decreased colon length. The
129 Abh2'-Abh3-'- mice trended towards a greater decrease in colon length than those of
129 WT and 129 Abh2 4- mice but this decrease did not reach statistical significance
(Figure 3-3C).
DSS-alone treatment did not result in appreciable tumor induction; regardless of
genotypes, only 15% of mice developed tumors (Figure 3-4A) and the average number of
tumors per colon was less than one (Figure 3-4B), and there was no difference between
the genotypes. This is consistent with the histopathological (hyperplasia and
dysplasia/neoplasia) scores for these tissues (Figure 3-4C). Colons were scored for
inflammation, epithelial defects, crypt atrophy, dysplasia/neoplasia, and area of
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Figure 3-4 Tumor formation is not significant in Abh-deficient and WT animals in DSS alone
treatment. (A) Tumor incidence and (B) tumor multiplicity. Data are mean ± SD. Black bars
represent historical data in C57BL/6 from previous study (11). (C) Histopathological scores for
severity of inflammation, epithelial defects, crypt atrophy, hyperplasia, dysplasia/neoplasia, and area
affected. Lines indicate mean scores. Histopathological scores of WT and Aag-/- animals in
C57BL/6 are historical data from previous study (11).
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dysplasia/neoplasia. Figure 3-4C shows that all animals of the different genotypes
experienced similarly high degrees of severity in colon in the different criteria induced by
7 cycles of DSS.
In summary, with 7 cycles of DSS treatment, no significant difference was found in
tumor development in any genotype. However, an increase in spleen weight was seen for
129 Abh2-'Abh3-1- mice compared to 129 WT and 129 Abh2 -'- mice. Although not
statistically significant, the change in colon length for 129 Abh2-'-Abh3 - - mice was
slightly larger than that of 129 WT and 129 Abh2 - - mice. Tumor incidence and
multiplicities were low in all genotypes, consistent with previous studies on B6 Aag -'- and
B6 WT animals with the same protocols (9). Because there was no significant colon
tumor formation in the DSS alone treatment scheme, we subsequently adopted another
treatment scheme that includes tumor initiation with an initial AOM treatment.
3.3.3. 129 Abh2 / and Abh3- animals experience greater sensitivity and tumor
development than WT animals following AOM+DSS treatment.
The DSS-alone treatment resulted in severe general pathologies but very little tumor
formation. Since we are interested in the protective role of DNA repair in chronic
inflammation and its relation with cancer, we utilized another treatment scheme. Tumor
initiation by the DNA alkylating agent AOM, followed by promotion by DSS-induced
inflammation is known to be effective for inducing colon tumors in mice.
In the AOM+DSS treatment scheme (Figure 3-1B), both 129 Abh2 -'- and 129 Abh2 -f-
Abh3'- mice were slightly more sensitive than the 129 WT mice in terms of survival,
although the differences did not reach statistical significance (Figure 3-5A). Moreover,
similar to observations in the DSS alone study, Abh2-Abh3' - mice displayed
significantly larger spleens than WT (p=0.0021) (Figure 3-5B), whereas Abh2 -- mice
only showed a slight increase in spleen weight that did not reach statistical significance.
Also, as with DSS alone treatment, the change in colon length did not differ for Abh2-l -
and Abh2-'-Abh3-'- mice compared to WT (Figure 3-5C). As expected, with an initial
treatment of a DNA damaging agent, tumor incidence and tumor multiplicity were
significantly higher than those in the DSS-alone treatment. In the AOM+DSS treatment
scheme, the majority of the mice developed tumors. In fact, 83% of WT in 129
background and 100% of Abh2 -'- and Abh2 Abh3' mice developed colon tumors (Figure
3-6A). Similar to the increases in spleen weights observed in both DSS alone and
AOM+DSS treatments, Abh2-'Abh3 -'- mice developed significantly more tumors with
respect to both WT (p=0.0204) and Abh2 - - (p=0.0424) mice (Figure 3-6B). This
demonstrates that a deficiency in both Abh2 and Abh3 renders mice slightly more
susceptible to the induction of colon tumors by AOM+DSS.
Histopathological scores among these genotypes were similar in most criteria, except
where Abh2-'-Abh3 -' animals exhibited significant increase in the amount of hyperplasia
found in the colon tissue when compared to WT (p=0.0012), consistent with the
increased number of tumors in these animals (Figure 3-6C). As expected, animals treated
with AOM+DSS scored higher in dysplasia/neoplasia and the magnitude of its affected
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Figure 3-5 Mice deficient in Abh are susceptible to AOM+DSS treatment. (A) Kaplan-
Meier survival curves for the various genotypes in the study. (B) Spleen weight as a
percentage of body weight. Data are mean ± SD. (C) Change in colon length. Data are
mean ± SD.
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Figure 3-6 Tumor formation is significant for mice deficient in Aag and Abh in AOM+DSS
treatment. (A) Tumor incidence and (B) tumor multiplicity. Data are mean + SD. (C)
Histopathological scores for severity of inflammation, epithelial defects, crypt atrophy,
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area than those in the DSS alone study, confirming that AOM+DSS treatment gives rise
to a greater extent of abnormal cell proliferation, consistent with the model leading to
higher number of tumors. Taken together, these results show that sensitivity due to the
lack of Abh2 is not apparent in the AOM+DSS treatment; however, deficiency in both
Abh2 and Abh3 together appears significant in giving rise to a sensitive response to
colitis, as with the DSS alone treatment.
3.3.4. Abh2- or Abh3 in conjunction with Aag mutant mice display more
pronounced inflammation phenotype than WT animals following AOM+DSS
treatment.
Given the overlap in substrate preference between the Abh2/3 proteins and Aag, we next
wanted to determine if the absence of Aag would confer greater sensitivity to Abh-
deficient mice. Aag-deficient mice were previously demonstrated to exhibit a
significantly more sensitive phenotype than WT animals to AOM+DSS treatment (9).
We set out to determine whether the absence of Abh2 or Abh3 in an Aag-deficient strain
would further increase sensitivity since none was seen for the single Abh2 mutant
following AOM+DSS treatment. We treated WT, Aag-l-, Aag-l-Abh2 - - and Aag--Abh3-
mice with AOM+DSS as described in Figure 3-lB. Note that all the strains in this study
were on a mixed 129/B6 strain background. Interestingly, there was a significant
decrease in survival (Figure 3-7A) compared to 129/B6 WT mice for 129/B6 Aag--
(p<0.0001), 129/B6 Aag--Abh2 -'- (p=0.0008) and 129/B6 Aag'-Abh3- - (p=0.0011).
Consistent with decreased survival, we also observed other disease markers elevated in
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Figure 3-7 Mice deficient in Aag and Abh are susceptible to AOM+DSS treatment. (A)
Kaplan-Meier survival curves for the various genotypes in the study. (B) Spleen weight
as a percentage of body weight. Data are mean ± SD. (C) Change in colon length. Data
are mean ± SD. Black bars represent historical data in C57BL/6 from previous study
(11).
Survival rates -- AOM+DSS
0 10 20 30 40 50 60 70 80 90 100 110
Number of days
p=0.0076
B
0
o.
Ch
p=O.0006
P<O. 1 P=0.0001
,o 307'
E1
0
E
0
I
area affected
p=0.0006
p=0.0040
p=0 0296
' W
fr
1*- ce
Figure 3-8 Tumor formation is significant for mice deficient in Aag and Abh in AOM+DSS
treatment. (A) Tumor incidence and (B) tumor multiplicity. Data are mean ± SD. Black bars
represent historical data in C57BL/6 from previous study (11). (C) Histopathological scores
for severity of inflammation, epithelial defects, crypt atrophy, hyperplasia,
dysplasia/neoplasia, and area affected. Lines indicate mean scores. Histopathological scores
of WT and Aag-/- animals in C57BL/6 are historical data from previous study (11).
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these repair-deficient mice. For example, spleen weight increases were seen in Aag-'-
(although not quite significant), Aag- Abh2 -'- (p=0.0209) and Aag-'Abh3-' (p=0.0076)
mice when compared to WT (Figure 3-7B). Similarly, Aag-', Aag-'Abh2-'-, and Aag- -
Abh3-'- all showed significant decreases in colon length compared to 129/B6 WT (Figure
3-7C), indicating severe colon pathology. In the AOM+DSS treatment scheme, all of the
mice, regardless of genotypes, developed colon tumors (Figure 3-8A). Figure 3-8B
shows tumor multiplicity; compared to WT mice, Aag-'- (p<0.0001), Aag-'Abh2-'-
(p=0.0006), and Aag-'-Abh3-'- mice all developed substantially more tumors. However, in
the Aag-deficient background, the addition of Abh2 or Abh3 deficiency did not lead to
more tumors. In addition to tumor formation, sensitivity in the colon was also evident by
histopathological analysis. Figure 3-8C shows the histopathological analysis in the
following criteria: inflammation; epithelial defects; crypt atrophy; hyperplasia;
dysplasia/neoplasia; and area affected. The histopathological scores in all criteria showed
high levels of damage in the colon. These results confirm that Aag has a protective role
in preventing the formation of colon tumors and relieving pathology in response to
chronic inflammation. Together these data indicate that with the AOM+DSS treatment,
the absence of the single Abh2 or Abh3 gene resulted in no additional sensitivity in Aag-
deficient mice; thus, Aag appears to be the predominant DNA alkylation repair protein
for rescuing mice from the effects of chronic colonic inflammation.
3.4. Discussion
Colorectal cancer is the second most common cancer in the Western world, accounting
for about 10% of cancer deaths in the U.S. in 2005 (27). Studying inflammation and its
contribution to cancer is important because patients with chronic IBD (ulcerative colitis
or Crohn's disease) are at greater risk of developing colorectal cancer (31, 32),
suggesting chronic inflammation is a major risk factor for this disease (33, 34). The risk
of colorectal cancer increases with extent of disease and duration, with an increase of 0.5-
1% per year after 7 years of colitis (31).
In the present study, episodic inflammation (induced by the colonic irritant DSS) was
simulated in wild-type and DNA repair-deficient mice lacking Abh2, Abh3, or Aag. As a
carcinogen that is used to induce colon cancer in rats and mice, a single dose of AOM
alone does not induce colon cancer. Chronic inflammation provoked by repeated cycles
of DSS with a preceding treatment with AOM is necessary for cancer since significant
tumorigenesis has been seen in previous mouse model studies (9, 30). We report here
that repair deficiency in Aag, Abh2 and Abh3 contributes to increased disease and
pathology in response to DSS-induced chronic inflammation, both in the absence and
presence of initial DNA damage by AOM. With treatment of AOM+DSS, increased
tumor formation was seen in the absence of alkylation repair proteins Aag and/or Abh2
and Abh3. Tumor formation was significant in AOM+DSS treatment for all animals,
regardless of genotype, compared to the treatment with DSS alone, which is not always
effective in inducing a robust neoplastic or tumor response.
Because the Abh knockout mice were originally made in the 129 background and Aag
knockout mice in the B6 background, Aag and Abh double knockouts are in a mixed
129/B6 background. To generate the double knockout mice in a pure background strain
would require over two years and 10 generations of backcrossing. Therefore, these
experiments were carried out in the mixed background. Unfortunately, an unavoidable
drawback of this experiment is the difficulty in comparing phenotypes in the different
backgrounds. We show that WT 129 mice show increased susceptibility to treatment
including lower survival, larger decrease in colon length, higher tumor multiplicity, and
higher histopathological scores when compared to the mixed 129/B6 or pure B6 strains.
It has been reported that genetically engineered mice in the 129/Sv strain appears
susceptible to IBD-like disease while those in the B6 background are more resistant to
IBD-related tumorigenesis in comparison with 129 and other genetic backgrounds (35).
Our results are consistent with previous studies which demonstrated differential
susceptibility of inbred mouse strains to DSS-induced colitis (acute inflammation with 1
cycle of DSS) including differences in histological lesions in ceca and colons in terms of
severity, ulceration, hyperplasia, and area involved (36). Some strains including B6 and
129/SvPas (a different substrain of 129/Sv than the one used in this study) showed
different degrees of susceptibility at different anatomical sites in that they were relatively
and strongly resistant in the cecum, respectively, but both showed susceptibility in the
colon (36). Since the B6 strain is known to be more refractory to tumors of epithelial
origin (37), its resistance compared to the 129 strain is not surprising.
The protective nature of Aag is presumably due to the fact that it can repair DNA from a
wide variety of damages. However, an excess of Aag-initiated abasic site intermediates
leading to strand breaks would have detrimental effects. Deficiency in repair proteins
such as Aag or the direct repair proteins Abh may lead to higher susceptibility to
mutations and cancer, as DNA damage brought about by RONS would be unrepaired. It
was shown in this study that during chronic inflammatory colitis, alkylation repair
deficient mice are prone to develop more tumors than WT. Using the DSS alone and
AOM+DSS model of colitis, the sensitive phenotype of mice deficient in Abh and/or Aag
repair was shown in response to chronic inflammation, as seen in the increase in spleen
weight, decrease in colon length, and tumor formation. However, lack of either Abh2 or
Abh3 alone does not always lead to such sensitivities, likely due to compensation by Aag
or other Abh proteins. It is very likely that the interplay and overlap in substrate
specificity (etheno base lesions) among Aag, Abh2, and Abh3 allow them to substitute
for one another to ensure cancer-free survival.
Significantly increased number of tumors were seen in the AOM+DSS scheme with
Abh2-'-Abh3' -, Aag-l-, Aag-'Abh2-'-, and Aag-'Abh3-- mice, when compared to WT mice in
the appropriate genetic background. Supported also by increased spleen weight and
decreased colon length, these results demonstrate that Abh2 and Abh3 together show
combined effects, but that their individual effects are not obvious, in the presence or
absence of Aag. It is possible that their individual effects are too small to be observed in
this assay by these endpoints. Alternatively, it is also possible that Abh2 and Abh3 can
repair inflammation-induced damages that cannot be repaired by Aag. If Abh2 and Abh3
work together to have a protective role and depend on each other for maximal function, it
would be important to see whether Abh3-' single mutant would show any measurable
phenotype. In protecting animals against chronic inflammation, Aag appears to have a
more prominent role. Similarly, since the absence of Aag masks the sensitivity due to the
individual effects of Abh2 or Abh3, and the double knockouts of both Abh2 and Abh3
lead to greater sensitivity than either mutant alone, it would be interesting to examine
sensitivity to AOM+DSS in the Aag-'Abh2-'Abh3-' triple mutant to confirm the
combined effects of Abh2 and Abh3. It would be expected that the triple mutant would
be much more sensitive than Aag-' alone because Abh2-'-Abh3 -'- mice appeared more
sensitive than either Abh2 -'- or Abh3-'- single mutant alone from this study.
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3.6. Appendix
Colon scoring criteria:
Inflammation
0: Normal
1: Small leukocyte aggregates in mucosa and/or submucosa
2: Coalescing mucosal and/or submucosal inflammation
3: Coalescing mucosal inflammation with prominent multifocal submucosal extension +/-
follicle formation
4: Severe diffuse inflammation of mucosa, submucosa, & deeper layers
Epithelial defects
0: None
1: Focally dilated glands and/or attenuated surface epithelium, decreased goblet cells
2: Focally extensive gland dilation and/or surface epithelial attenuation
3: Erosions (mucosal necrosis terminating above muscularis mucosae)
4: Ulceration (full-thickness mucosal necrosis extending into submucosa or deeper)
Crypt atrophy (in region most affected)
0: None
1: <25%
2: -25-50%
3: -50-75%
4. >75%
Hyperplasia
0: Normal gland length
1: -1.5 X normal
2: -2 X; +/- mitotic figures 1/3 way up to surface
3: -3 X; +/- mitotic figures 1/2 way up to surface
4: -4X+; +/- mitotic figures >1/2 way up to surface
Dysplasia/Neoplasia
0: Normal
1: Aberrent crypt foci, dysplasia characterized by epithelial cell pleomorphism, plump &
attenuated forms, gland malformation with splitting, branching, and infolding
2: Polypoid hyperplasia/dysplasia, moderate dysplasia characterized by pleomorphism,
early cellular & nuclear atypia, piling & infolding, occasional cystic dilation, bulging
towards muscularis mucosae & projection into lumen, loss of normal glandular, mucous,
or goblet cells
3: Adenomatous and/or sessile hyperplasia/dysplasia; gastrointestinal intraepithelial
neoplasia (GIN) or carcinoma in situ, marked dysplasia confined to mucosa, features as
above but greater severity, frequent & sometimes bizarre mitoses
3.5: Intramucosal carcinoma (extension of severely dysplastic regions into muscularis
mucosae)
4: Invasive carcinoma: Submucosal invasion (differentiate from herniation) or any
demonstrated invasion into blood or lymphatic vessels, regional nodes, or other
metastasis.
Note: Dysplastic glands herniated into lymphoid follicles in an otherwise normal mucosa
are not scored. Dysplasia is a normal consequence of epithelial cell herniation into GALT.
Area of dvsplasia/neoplasia (in affected region of bowel)
0: None
1: <10% surface area
2: 10-25% surface area
3: 25-50% surface area
4: >50% surface area
Table 3-1: Comparison of disease markers in mice that survived to the end of the
treatment regime with those that died during study in DSS-alone treatment
Change in colon length is in cm
Spleen per body wt is in %
DSS only
mean values WT 129 Abh2 null 129 Abh2/3 null 129
change in colon length
END -1.4 -1.3 -1.9
DURING -1.5 -1.7
% spleen per body wt
END 0.9 0.9 2.1
DURING 0.4 5.5
tumof multiplicity
END 0.6 0.1 0.3
DURING 0 0
inflammation
END 2.7 3 2.7
DURING 2.8 2.1
epithelial defects
END 2.7 2.4 2.3
DURING 3.0 1.8
crypt atrophy
END 1.4 1.4 1.1
DURING 1.8 1
hyperplasia
END 1.8 1.5 1.7
DURING 1.2 1
dysplasia/neoplasia
END 1.2 1.4 1.3
DURING 1 1.4
area affected
END 1.5 1.4 1.5
DURING 1.2 1
Table 3-2: Comparison of disease markers in mice that survived to the end of the
treatment regime with those that died during study in AOM+DSS treatment
Change in colon length is in cm
Spleen per body wt is in %
AOM+DSS
Mean values WT Abh2 null Abh2/3 null Aaq null AanAbh2 null AagAbh3 null
129 129 129 C57B6/129 C57B6/129 C57B6/129
change in colon
length
END -1.1 -0.7 -1.4 -1.5 -2.0 -2.1
DURING -1.7 -2.1 -1.5 -2.1 -2.1 -1.8
% spleen per body wt
END 0.5 1.1 1.3 1.1 1.2 0.9
DURING 1.1 1.1 1.7 0.9 0.8 1.6
tumor multiplicity
END 10.8 10.8 20.0 18.5 21.6 11.8
DURING 12.8 12.3 20.7 21.4 21.7 23.3
inflammation
END 2.3 2.8 2.6 2 2.7 3.1
DURING 2.3 2.6 2.7 2.6 2.4 2.8
epithelial defects
END 2.8 2.3 2.6 2 2.1 3
DURING 2.3 2.6 2.7 2.6 2.7 2.4
crypt atrophy
END 1.2 1.4 1.1 0.8 1.4 1.8
DURING 1.1 1.4 1.3 1.3 1.4 0.6
hyperplasia
END 2 2.5 2.9 2.5 2.5 2.5
DURING 2.3 1.955 2.8 2.3 1.9 2.5
dysplasialneoplasia
END 2.6 3 3.1 3 3 3.6
DURING 3 3.1 3.2 3.1 2.9 3.4
area affected
END 2.3 2.4 2.7 2.3 2 3.2
DURING 2.5 2.6 3.1 2.3 2.6 3.4
4. CHAPTER 4 - Recognition and Processing of a New Repertoire of DNA Damages
by Human 3-Methyladenine DNA Glycosylase (AAG)
4.1. Introduction
DNA damaging agents are ubiquitous and cellular DNA is constantly attacked by a
variety of endogenous and exogenous DNA damaging agents. DNA can be deaminated
spontaneously or alkylated by endogenous intracellular agents and from environmental
exposures. Such damages can interfere with DNA replication and transcription, and may
be mutagenic or cytotoxic to the cell. During evolution, multiple DNA repair pathways
have evolved to maintain the integrity of DNA in all organisms. Among other pathways,
single base aberrations can be repaired by the base excision repair (BER) pathway. BER
is initiated by DNA glycosylases that recognize the damaged base in the genome,
followed by hydrolysis of the N-glycosylic bond, resulting in the release of the damaged
base and the generation of an abasic site. The abasic site is then further processed by an
AP endonuclease or AP lyase, resulting in a strand break. After trimming of the DNA
ends, DNA is resynthesized by a DNA polymerase and a DNA ligase seals the nick to
restore undamaged DNA (1).
Many DNA glycosylases exhibit strict substrate specificity. The human 3-methyladenine
DNA glycosylase (AAG), by contrast, is able to recognize and excise structurally diverse
bases, including 3-methyladenine, 7-methylguanine, 1-N6-ethenoadenine (EA), and
hypoxanthine (Hx) from DNA (2-8). The crystal structure of AAG bound to DNA
containing cA provides insight into the binding and catalysis by this DNA glycosylase.
In the active site complex, the substrate nucleotide is rotated in the plane of the base pair
out of the duplex DNA into the active site of the enzyme. Tyr162 of the enzyme is
intercalated into the space vacated by the lesion via the DNA minor groove, maintaining
proper base stacking and minimizing DNA distortion (9, 10). A water molecule is
involved in the nucleophilic attack on the N-glycosylic bond by an acid-base catalytic
mechanism with Glu125 acting as a general base (9-11). Equally important, the
discrimination against pyrimidines is likely due to the fact that AAG employs an acid-
base catalysis that is more suitable for selective excision of purines (11). In addition, the
possible steric clash of an active site residue side chain (Asnl69) with the 2-amino group
of guanine plus the inability of adenine to accept a hydrogen bond from His 136 may
exclude these undamaged purine bases from the binding pocket (10, 12).
In contrast to AAG, AlkB is an orthogonal DNA repair protein that can directly reverse
alkylation damage catalytically. The E. coli AlkB is a direct reversal protein, which was
shown in the recent years to repair methylated lesions such as 1-methyladenine (1MeA)
and 3-methylcytosine (3MeC) in DNA and RNA (13, 14) via oxidative demethylation.
Subsequently, 1-methylguanine (1MeG) (15, 16), 3-methylthymine (3MeT) (15-17), and
3-ethylcytosine (15) were also found to be AlkB substrates, although with weaker activity
on 1MeG and 3MeT than on lMeA and 3MeC. Of the human AlkB homologs
discovered thus far, only hABH1, hABH2, and hABH3 have been shown to have repair
activity on DNA and also RNA (14, 18-21). In addition to simple methylated base
adducts, AlkB was recently shown to repair 1,N6-ethanoadenine (EA) (22), eA (23, 24)
and 3,4-ethenocytosine (SC) (23). In vivo (in mouse) and in vitro repair activity on cA
have been shown for mammalian ABH2 (25).
Although E. coli AlkB and the human ABH proteins are able to repair etheno lesions,
their chemical mechanism is quite different from AAG-initiated BER, which also serves
to repair FA and EA DNA lesions. Etheno base lesions can be formed endogenously by
the products of lipid peroxidation, and can be induced by exposure to environmental
sources such as vinyl chloride and its metabolites chloroethylene oxide and
chloroacetaldehyde (26-33). EA is similar to EA with the exception of having a saturated
C-C bond in place of the double bond between the two exocyclic carbon atoms bridging
the N6 exocyclic and N1 heterocyclic nitrogens of adenine. EA can be formed from the
reaction between DNA and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) (34), which is
often used to treat brain tumors; EA can be repaired by AAG, albeit inefficiently (35).
Having two different mechanisms for the repair of such an important class of lesions
could be advantageous, and the relative activities of each pathway may differ between
tissue and cell types.
Given that AlkB and AAG have overlapping roles in the repair of the clinically relevant
exocyclic lesion, 1,N6-ethenoadenine, we set out to uncover further substrate specificity
shared between these two proteins in order to explore the redundancy in their roles. In
the present study, we have tested the binding and glycosylase activity of AAG against a
library of lesion-containing DNA oligonucleotides (Figure 1) and have identified new
substrates for AAG. Both the full-length and a truncated version of AAG missing the N-
terminal 80 amino acids (A80) were used in this study, whereas previous studies
primarily focused on A80AAG because it is more easily purified. We have shown that
IMeG, in addition to the already-known substrates aA and EA, is a substrate shared
between AAG and AlkB. To our surprise, we found that both the truncated and full-
length AAG excise gA and Hx from single-stranded DNA. Based upon earlier work
showing that FA and Hx are refractory to repair when situated opposite a reduced basic
site (36), it was thought that excision is only possible in duplex DNA. Furthermore, we
found that both full-length AAG and A80AAG have weak glycosylase activity on 1,N2-
eG. Finally, we found that only full-length AAG, but not A80AAG, excises uracil in both
ss- and ds-DNA. We demonstrate here, using a comprehensive library of lesion-
containing single- and double-stranded DNA oligonucleotides, that AAG has a wide
range of substrate specificity including multiple classes of new substrates.
4.2. Materials and Methods
4.2.1. DNA Oligonucleotides.
Oligonucleotides containing 1MeG, IMeA, 3MeT, and 3MeC were synthesized as
described by Delaney and Essigmann (15). The synthesis of the oligonucleotide
containing EA was described by Frick et al. (22), those containing EA and EC by Delaney
et al. (23), 1,N2-eG by Zang et al. (37), M1G by Wang et al. (38), and the synthesis of
oligonucleotides containing 3MeU and 3EtU will be published elsewhere.
Oligonucleotides containing Hx and U were synthesized using phosphoramidites from
Glen Research (Sterling, VA). All of the oligonucleotides were 16-mers with identical
sequence (5'GAAGACCTXGGCGTCC3') where the only difference is in the central
lesion, X. The single stranded oligonucleotides were 5'-end-labeled with 32P and purified
with a MicroSpin G-25 column (GE Healthcare). For studies involving double-stranded
DNA substrates, annealing was performed using a 1:1.5 ratio of modified:unlabeled
complement. The base opposite the lesion was chosen to be the natural base-pairing
partner of the undamaged base. For U, 3MeU and 3EtU, guanine was used as the
opposing base, since the lesions here were assumed to form from deamination of cytosine
and 3-alkylcytosine.
4.2.2. AAG protein expression and purification.
The truncated mutant with the first 80 amino acids deleted from the N-terminus, and the
full-length AAG protein were both used in this study. The A80AAG and full-length
AAG proteins were cloned and purified as described (11) with and without the gel
filtration step, respectively. Previous studies have shown that AAG possessing a
truncation of its N-terminal domain has catalytic activity similar to that of the full-length
protein (5, 11).
4.2.3. DNA Glycosylase Activity Assays.
Glycosylase assays were performed by incubation of 1000 nM AAG protein (10 pmol)
and 10 nM of a 32 P-labeled DNA substrate (100 fmol) at 370C in 10 gL assay buffer
containing 20 mM Tris-HCl buffer, pH 7.8, 100 mM KC1, 5 mM f3-mercaptoethanol, 2
mM EDTA, 1 mM EGTA, and 50 gg/mL BSA. The experiments were carried out under
single-turnover conditions where the enzyme concentration (1000 nM) was in large
excess of the labeled DNA substrate concentration (10 nM). Initial screening
experiments of AAG glycosylase activity were performed by incubating a 1:100 molar
ratio of DNA oligonucleotide : AAG enzyme in the glycosylase buffer for 90 minutes (or
180 minutes for 1,N2-eG and uracil). For subsequent kinetics experiments, an aliquot of
the reaction mixture was removed for quenching at various time points during the course
of the incubation. Reaction mixtures were quenched with 0.2 N NaOH, except for EC
and 3MeC where 0.2 M piperidine was used to eliminate spontaneous cleavage, and then
heated at 750C for 15 minutes to cleave the DNA at AP sites. Samples were then diluted
with formamide loading buffer and cleavage products were resolved on a 20% denaturing
polyacrylamide gel. The fraction of uncleaved versus cleaved substrate was determined
on a Packard Cyclone PhosphorImager (Packard Instruments, Meridien, CT), analyzed
with OptiQuant analysis software (Packard Instruments, Meridien, CT), and quantified
with the Kodak 1D scientific imaging software (Eastman Kodak Campany, New Haven,
CT).
Enzymatic rate constants were determined by fitting the single-turnover kinetic data into
the One Phase Exponential Association equation (Equation 1) in the GraphPad Prism
software (GraphPad Software, Inc., La Jolla, CA):
Y=Ymax (l-e -kobs) (1)
where y is the amount of substrate cleaved at any particular time point, ymax is the
maximum amount of cleaved substrate, t is time, and kobs is the observed rate constant.
Rate constants for extremely slow reactions where the increase in cleaved substrate
amount did not follow an exponential increase were determined using linear regression in
the form of y=kobst.
4.2.4. Electrophoretic Mobility Shift (Gel Shift) Assays.
Binding assays were performed in an assay buffer containing 50 mM HEPES, pH 7.5,
100 mM NaCL, 5mM f3-mercaptoethanol, 9.5% v/v glycerol, and 0.1 mg/mL BSA. 32p_
Labeled DNA substrate (2 nM) was incubated with increasing concentrations of AAG in
the binding assay buffer for 30 minutes at 40C and then directly loaded onto a 6% non-
denaturing polyacrylamide gel. After running the gel, it was dried and the fraction of
DNA bound by AAG was analyzed as described above for the glycosylase assays. The
apparent dissociation constant Kd was calculated by fitting the quantified binding data
into the One Site Binding (Hyperbola) equation (Equation 2) in the GraphPad Prism
software (GraphPad Software, Inc., La Jolla, CA).
B max xy 
-m-- (2)
Kd + X
where y is the total amount of bound substrate, Bmax is the maximum specific binding, x is
the concentration of the protein, and Kd is the apparent binding constant.
4.3. Results
4.3.1. AAG recognizes a wide range of substrate structures
In order to investigate thoroughly the substrate specificity of AAG, an extensive library
of lesion-containing DNA oligonucleotides was used (Figure 4-1). Substrate binding and
glycosylase activity of both the A80 and full-length AAG proteins were measured for
single- and double-stranded lesion-containing DNA oligonucleotides. Their identical
sequence context allows us to eliminate the possible effects resulting from the flanking
base sequence on the protein's binding and excision ability. Lesion recognition and
substrate binding was measured by gel-shift assays. Figure 4-2 (left panel) summarizes
the binding results at an AAG concentration of 200 nM, with a DNA: protein molar ratio
of 1:100 to obtain single-turnover kinetics. Surprisingly, AAG was found to bind a large
number of lesions in duplex DNA, but to different extents (Figure 4-2). Note that
A80AAG binding was only detected for double-stranded DNA and not for single-
stranded DNA (data not shown). AAG bound several AlkB substrates; these include
simple methylated bases (1MeG, 1MeA, 3MeT and 3MeC), EA, cA and EC. The
apparent relative strength of binding was as follows: EA and EC > 3MeC > 1MeA >
3MeT > EA > 1MeG (Figure 4-2). It is also interesting to note that, in addition to EA and
EC, AAG showed very strong binding to 3-methyluracil (3MeU) and 3-ethyluracil (3EtU)
but not to uracil itself. Very weak binding for 1,N2-eG was seen, but no binding was
H, H.3 HC H3 H3 N HA
DNA DNA DNA DNIA DNA DNA
1MeG 1MeA 3MeT 3MeC 3MeU 3EtU
DNA DNA DNA DNA DNA DNA DNA
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Sequence of oligonucleotides
5'-GAAGACCTXGGCGTCC-3'
Figure 4-1. Chemical structures and sequence context of the different DNA lesions
tested in the present study.
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Figure 4-2. AAG binds to a wide range of substrates but excises only a few, as
shown in initial screening experiments. Binding and excision are based on % bound
(with 2nM substrate and 200nM AAG, a 1:100 molar ratio of substrate to AAG)
and % cleavage (at 90 min-incubation for most lesions or 180 min-incubation for
1,N2-eG and U), respectively. Reaction conditions were as described in "Materials
and Methods".
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detected for M1G. It is interesting to note the difference in binding affinity of U, 3MeU,
and 3MeT in relation to their structural similarity. 3MeU differs from U by the addition
of a methyl group on the N3 position, yet this modification is sufficient to increase its
binding affinity to AAG significantly to a KI of -30 nM compared with no binding
shown by U. However, the binding affinity of 3MeT (about 200 nM), which has methyl
groups on both the N3 and C5 positions of uracil, was much lower than that of 3MeU. In
addition, it is important to note that for all of the lesions tested, band-shifts were only
observed for the truncated A80AAG (Figure 4-2) and not with the full-length protein.
This behavior in gel shift assays was observed before and is likely due to the limitation of
this method (unpublished observation). However, using plasmon surface resonance, full-
length AAG has been shown to bind to DNA oligonucleotides containing Hx and AP
sites (39).
To determine the quantitative binding affinity of AAG to the base lesions, shown in
Figure 4-1, various concentrations of AAG were incubated with a fixed amount of
substrate in duplex DNA. Figure 4-3 shows representative experiments for a weak-
binding substrate (1MeG), a moderate binding substrate (3EtU), and a very strong
binding substrate (EA) (Figure 4-3A, C, and E), with corresponding quantification of the
binding (Figure 4-3B, D, and F), from which the apparent dissociation constants (Kd)
were calculated (Table 4-1). AAG showed a wide range of binding affinities to the
various lesions. The strongest affinitiy was observed for FA and cC, with a Kd of
approximately 10 nM, followed by 3MeU with a Kd - 30 nM. AAG exhibited moderate
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Figure 4-3. AAG binds to different lesions with different affinities. Gel mobility
shift assay for the binding of AAG to oligonucleotides containing (A) 1MeG, (C)
3EtU, (E) cA. Graphical representation of the binding of AAG to (B) 1MeG, (D)
3EtU, (F) EA.
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binding affinity for 3MeC, Hx, 3EtU, 1MeA, and 3MeT, with apparent Kd's between 60
and 200 nM. Weak to very weak binding was observed for EA (Kd = 340 nM), IMeG
(Kd = 650 nM), and 1,N2-FG (Kd = 930 nM).
4.3.2. AAG excises only a few of the lesions to which it binds.
We tested the glycosylase activity for both the A80 and full-length AAG on the library of
lesion-containing oligonucleotides. The glycosylase reactions were carried out under
single-turnover conditions where the enzyme was in 100-fold molar excess of the
oligonucleotide substrate, such that the reaction kinetics should not be a function of
enzyme-substrate binding rates (12). Single turnover glycosylase kinetics measure the
rate of reaction steps after forming the initial AAG-DNA complex (12). From the initial
screening of glycosylase activity (Figure 4-2), it seemed that of the damaged bases tested,
AAG was active on 1MeG, EA, EA, Hx, 1,N2-eG, and uracil in double-stranded DNA and
also eA, Hx, and uracil in single-stranded DNA. The truncated and full-length AAG
appeared to exhibit very similar excision kinetics for most substrates except for U. No
glycosylase activity was found toward 1MeA, 3MeT, 3MeC, 3MeU, 3EtU, EC, and M1G
(Figure 4-2).
Based on the screening studies (Figure 4-2), we went on to measure detailed base
excision kinetics for the substrates that AAG was able to excise. Single-turnover
glycosylase activity assays were performed with time courses up to 90 or 180 minutes,
depending on the reaction rates. Of the various AlkB substrates tested (1MeG, 1MeA,
3MeT, 3MeC, EA, EA and eC), AAG-mediated excision was only observed for IMeG,
EA, and EA. Thus, among the methylated AlkB substrates, IMeG was the only lesion to
be repaired by AAG, with a fairly fast observed rate constant of -0.1 min -1 for both the
A80 and full-length AAG (Table 4-1, Figure 4-4A-B). It is interesting that despite
AAG's ability to bind to all four methylated lesions, only 1MeG was excised, even
though AAG bound 1MeG the least tightly among the four (Table 4-1). Although the
purine site of alkylation for 1MeG is identical to 1MeA, AAG could not excise 1MeA
(Figure 4-2). 3MeT and 3MeC are pyrimidines and are not expected to be excised by
AAG based on the acid-base catalytic mechanism that favors the removal of damaged
purines (11). Two other AlkB substrates repaired by AAG were EA and EA in duplex
DNA. Guliaev et al. (35) previously reported that EA is a 65-fold weaker substrate for
AAG than LA; however, our present study shows the excision rates of EA and EA to be
far less disparate with respective initial rates of 0.5 fmol/min and 2.0 fmol/min (Table 4-1,
Figure 4-4C-D, Figure 4-5A-B). No glycosylase activity toward eC was observed despite
AAG's very strong binding affinity for this lesion (Figure 4-2, Table 4-1).
4.3.3. Single-turnover kinetics of excision of 1,N6-ethenoadenine and hypoxanthine
from single- and double-stranded DNA
The activity of AAG on its well known EA and Hx substrates was measured in detail for
comparison to its activity on the library of substrates within the same sequence context;
excision kinetics for A80AAG and full-length AAG were monitored for up to 90 minutes
(Figure 4-5). The observed rate constant for EA:T was found to be -0.03 min -' for A80
no
AAG IMeG:C A80AAG
substrate
IMeG:C AAG
3 180
Excision Kinetics of 1MeG:C by AAG
100,
E 75-
0
. 50,
* 2511
SA80AAG
AAAG
0 20 40 60 80 100 120 140 160 180 200
Time (min)
EA:T A80AAG
EA:T AAG
3 1801 -- l~
Excision Kinetics of EA.T by AAG
G
G
0
Time (min)
Figure 4-4. 1MeG and EA, known AlkB substrates, are cleaved by AAG when
present in double-stranded DNA. Glycosylase activity of AAG toward (A) 1MeG
and (C) EA. No AAG represents incubation without AAG for the longest time point
of the assay. Graphical representation of the glycosylase activity toward (B) 1MeG
and (D) EA by (M) A80AAG and (A) full-length AAG. For comparison with EA,
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and full-length AAG (Table 4-1) and those for Hx:T were about 0.4 min-' (Table 4-1);
clearly, the excision rates for the truncated and full-length AAG were very similar. AAG
unexpectedly also exhibited catalytic activity against EA and Hx in single-stranded DNA
(Figure 4-5A, C, D, F). Although most previous studies have monitored AAG activity on
duplex DNA, activity on single-stranded DNA was previously reported for oxanine and
EA (40). Of all the adducts tested in the present study, the only substrates that could be
excised from single-stranded DNA by AAG were EA and Hx (and uracil, which is weakly
excised). Interestingly, the observed rate constants for EA in single- and double-stranded
DNA were very similar (approximately 0.03-0.04 min-', Table 4-1) and the initial
excision rates were only slightly higher (less than one-fold increase) for duplex DNA
than for single-stranded DNA (Table 4-1). On the other hand, the observed rate
constants for Hx in single-stranded DNA (-0.06 min-', Table 4-1) were about seven-fold
lower than those in duplex DNA (-0.4 min-', Table 4-1).
4.3.4. Both A80AAG and full-length AAG excise 1,N2-eG
It was previously shown that glycosylase activity toward 1,N2-EG in duplex DNA was
observed for full-length AAG, but not for the truncated form of AAG lacking the first 73
amino acids (41). It was also shown that the inability to excise was not due to an
inability to bind, since the truncated form of AAG was observed to bind 1,N2-eG (41);
thus, it was concluded that the nonconserved, N-terminal part of AAG was essential for
glycosylase activity toward 1,N2-EG (41). However, here we show that both the
A80AAG and the full-length AAG were able to cleave 1,N2-EG from double-stranded
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Figure 4-6. 1,N2-G in double-stranded DNA is a substrate for both the A80
truncated form and the full-length AAG protein. (A) Glycosylase activity of AAG
toward 1,N2-EG by A80 and full-length AAG. No AAG represents incubation
without AAG for the longest time point of the assay. (B) Graphical representation
of the glycosylase activity toward 1,N2-EG by (U) A80AAG and (A) full-length AAG.
~-:: ::;~"
DNA, albeit to a limited extent. As seen from Figure 4-6, both forms of the protein
excised about 6% of the 1,N2-eG base lesion at saturation, with an observed rate constant
of 0.08 and 0.07 min -' for A80 and full-length AAG, respectively (and initial rates of -0.5
fmol/min) (Table 4-1). Such rate constants were among the third-highest of the lesions
tested in this study, while the corresponding initial excision rates turned out to be very
low. However, neither AAG glycosylase activity nor binding was observed for the
structurally similar M1G adduct (Figure 4-1, Figure 4-2).
4.3.5. Excision of uracil from single- and double-stranded DNA by AAG.
In addition to hypoxanthine (the deamination product of adenine), AAG has been shown
to excise the guanine-derived deaminated bases xanthine (42) and oxanine (40). Here,
we show that deaminated cytosine, namely uracil (U), can also be excised by AAG,
although very slowly (Figure 4-7A-C and Table 4-1). Moreover, similar to oxanine,
AAG can excise U from both single- and double-stranded DNA; however, only the full-
length AAG exhibited such activity. The single-turnover excision with U appeared to be
very slow and showed kinetics that followed a linear rather than an exponential fit,
yielding initial excision rates (and also observed rate constants) of -0.06 fmol/min for
both single- and double-stranded DNA (Table 4-1), which is about 7-fold lower than
those of 1,N2-EG, whose saturation cleavage was only about 6% (Figure 4-6B).
Although uracil can be weakly cleaved by AAG, the alkylated 3MeU and 3EtU
(deamination products of 3MeC and e3C, respectively) were not excised despite their
significant binding to AAG. In contrast, binding of both forms of AAG to substrates
containing U was not detected. Notably, among the substrates tested in this study, uracil
was the only substrate toward which the truncated and full-length AAG showed different
activity.
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Figure 4-7. Uracil is a substrate for the full-length AAG protein in both single- and
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Table 4-1. Binding and excision kinetic constants of various lesions by AAG.
A80AAGBase
excised:
pairing
partner
1MeG:C
1MeA:T
3MeT:A
3MeC:G
3MeU:G
3EtU:G
eA:T
EA:T
eC:G
1,M-eG:C
M1G:C
Hx:T
U:G
EA (ss)
Hx (ss)
U (ss)
A80AAG
K&S.d.
(nM)
648 ± 154
176 28
189 ± 35
61 ± 9
27 + 4
103 ± 12
7+ 1
340 ± 129
10± 1
928 ± 137
N.B.
125 30
N.B.
N.B.
N.B.
N.B.
Glycosylase Activity
ko~ns.d. (min )a
0.065 ± 0.005
N.A.
N.A.
N.A.
N.A.
N.A.
0.029 ± 0.003
0.016 ± 0.001
N.A.
0.074 ± 0.012
N.A.
0.390 ± 0.061
ko.s.d. (min- 
0.043 ± 0.005
0.061 ± 0.007
N.B. or N.A. represents no binding or no activity, respectively.
Full-length AAG was not observed to bind DNA at all in gel-shift assay.
A80 AAG was not observed to bind to single-stranded DNA.
Full-length AAG
kobW s.d. Initial excision
(fmol/min)c rate
(fmol/min)b
3.68
N.A.
N.A.
N.A.
N.A.
N.A.
2.12
0.51
N.A.
0.46
N.A.
27.6
0.062 + 0.002 c 0.062c
k,±s.d. (minl)a
0.101 ± 0.010
N.A.
N.A.
N.A.
N.A.
N.A.
0.027 ± 0.003
0.017 ± 0.001
N.A.
0.079 ± 0.011
N.A.
0.425 ± 0.070
N.A.
kob±s.d. (min)"
0.030 ± 0.006
0.062 ± 0.011
N.A.
Initial excision
rate
(fmol/min)b
4.46
N.A.
N.A.
N.A.
N.A.
N.A.
1.98
0.47
N.A.
0.44
N.A.
30.4
N.A.
1.22
2.01
N.A.
aActivity rate constants kobs were determined from one-phase exponential association except for
U.
blnitial rate is the product of the rate constant kobs and the maximum saturation cleavage
(maximum amount of abasic product formed), except for U where the initial rate is equal to the
rate constant obtained from linear regression.
cRate data for U were fitted with linear regression in the form of y=kt.
0.063 + 0.003 C
Binding
1.65
1.90
0.063c
4.4. Discussion
The human 3-methyladenine DNA glycosylase (AAG) is known to have a broad substrate
specificity for damaged purines including 3-methyladenine, 7-methylguanine, EA, and Hx
(2-8). In this report, we examined excision kinetics and substrate binding of both
truncated A80 and full-length AAG, for an extensive library of lesion-containing DNA
oligonucleotides in both the single- and double-stranded form. In addition to confirming
previous findings, we identified several new substrates for AAG in single- and double-
stranded DNA, namely IMeG (ds), Hx (ss), 1,N2-eG (ds, excision by truncated A80AAG)
and uracil in ss- and ds-DNA (excision by full-length AAG).
Although human AAG has been primarily shown to repair lesions in double-stranded
DNA, excision activity on single-stranded DNA was previously observed, as shown in
repairing sA and oxanine (40). Binding and excision of oxanine in duplex DNA appear
to be independent of the opposite base; indeed, a complementary strand is not necessary
as seen from the similar binding and excision efficiencies for oxanine in 62-mer single-
and double-stranded DNA (40). In addition to AAG, other DNA glycosylases have been
shown to excise damaged bases from single-stranded DNA. For instance, in E. coli, the
3-methyladenine glycosylase (AlkA) has been shown to remove 3-methyladenine from
single-stranded DNA (43) and in mammals, the bovine uracil DNA glycosylase (UDG)
(44) and human SMUG1 (45) also excise uracil from single-stranded DNA substrate. In
the present study, we have observed AAG activity on lesion-containing single-stranded
DNA. We found both cA and Hx within single-stranded DNA to be good substrates for
AAG. EA was excised with similar observed rate constants in single- and double-
stranded DNA, although in single-stranded DNA the initial excision rates were lower
(Table 4-1). For Hx, it was previously shown that Hx could only be excised when paired
with a base, preferably T rather than C (36, 40, 46-48) and not in single-stranded DNA,
suggesting that it is the base-pair instead of the damaged base alone that affects the
recognition by AAG. However, to our surprise, we observed that Hx can also be repaired
in single-stranded DNA, although with observed rate constants of over 6-fold lower
(initial rates about 14-fold lower) than those in double-stranded DNA (Table 4-1).
Excision on the single strands may be possible because the reduced base stacking and the
lack of base-pairing may increase the chances of the damaged bases being captured from
the less rigid single-stranded structure. One might argue that the single-stranded DNA
may form a secondary structure containing duplex DNA, thus allowing excision to occur.
However, other than sA and Hx (and uracil to weak extent), no other substrates were
observed to be excised from single strands, indicating that lesion excision from single-
stranded DNA may be damage-specific. A previous report showed that AAG did not
bind or excise the DNA duplexes with EA or Hx paired opposite to an abasic site (36),
suggesting that the binding of damaged purine bases by AAG may require an opposite
base or an opposite strand. However, we demonstrated catalytic activity toward EA and
Hx in single-stranded DNA although no binding of AAG to single-stranded DNA was
detected by gel shift mobility assay.
During DNA replication and transcription, transient single-stranded regions may result
and expose more potential sites of damage on the DNA bases; therefore, it would be
beneficial to the cell if there is a mechanism for repairing damages on single-stranded
DNA, especially if they are replication- or transcription-blocking. Although the
advantage of base excision in single-stranded DNA is not evident, it is possible that in
vivo, with an abasic site or strand break, replication or transcription would stop.
Polymerase arrest could stimulate recombination and stalled RNA polymerase may
trigger transcription-coupled repair.
In addition to the aforementioned eA, we have also found that AAG and AlkB share other
classes of DNA damage as substrates such as EA and IMeG. Formed by chloroethyl
nitrosoureas in cancer therapy and structurally similar to EA, ethanoadenine (EA) was
recently shown to be metabolized by AlkB (22). Unlike EA whose unsaturated exocyclic
ring is planar, EA's non-planar saturated ring may give rise to less stable aromatic base-
stacking interactions with the active site residues of AAG, possibly leading to the lower
binding ability and less efficient repair of EA. Guliaev et al. (35) showed that AAG was
able to repair EA, but with a 65-fold lower efficiency than for EA. We, however, found
only about a four-fold difference in initial excision rates in this study (Table 4-1); this
discrepancy could be possibly due to differences in sequence context. AAG bound
somewhat weakly to EA, but excised it rather efficiently up to 30% of the substrate
(Figure 4-4C and D, Table 4-1). In addition to cyclic lesions (22-24), simple methylated
lesions such as 1MeG, 3MeT, 1MeA, and 3MeC also interfere with normal Watson-Crick
base-pairing and were all shown to be AlkB substrates (13-17). However, despite the
observed binding between AAG and these lesions, excision was only seen for IMeG
(Figure 4-2, Table 4-1, Figure 4-3A-B). It is also worth mentioning that binding affinity
clearly does not predict excision activity. For instance, AAG exhibited very weak
binding to 1MeG (Table 4-1, Figure 4-2, Figure 4-3) and yet it was able to excise -50%
of it at saturation (Figure 4-4A-B), making 1MeG among the top three lesions to be
excised. In fact, AAG only bound to Hx:T moderately well (with a Kd of 124.8 nM), but
showed the fastest excision rate (Table 4-1). Sometimes, strong binding substrates are
weakly excised and vice versa. Indeed, AAG does not excise all of the substrates to
which it binds. Hence, it is very difficult to point out any trends relating binding affinity
and excision rates.
We questioned why AAG can cleave 1MeG but not the structurally analogous 1MeA.
Some main differences between 1MeA and IMeG include the 06 atom of IMeG, which
can serve as a hydrogen bond acceptor from the main chain amide of His136 (Figure 4-8)
in the enzyme active site, whereas 1MeA has an amino group at the N6 position and
cannot accept the hydrogen bond for stabilization (which is how AAG discriminates
against normal adenines (10)). Moreover, IMeA is positively charged whereas 1MeG is
neutral and, like guanine, has a 2-amino group that could clash with Asn169 (this 2-
amino group is absent on 1MeA). Charge probably has little effect in the assistance of
glycosyl bond cleavage in this case, since the positively charged 1MeA is not a better
substrate than IMeG. Perhaps the hydrogen bond between the 06 position of the IMeG
base and His 136 enhances binding in the active site and plays a stronger role in
recognition and binding than the cation-at interaction between the positively charged
IMeA and the aromatic active site residues. The lack of excision of 3MeC and 3MeT
Figure 4-8. Structure of the AAG active site (green) showing the flipped-out EA
nucleotide (gold). The dashed line indicates a hydrogen bond between the N6 of EA
(acceptor) and the peptide amide (donor) of His136. This figure is generated using
the coordinates of the AAG/EA crystal structure (PDB ID: lf4r (10)) using Pymol.
was expected and may be explained by the fact that protonation of the nucleobase likely
occurs at N7 or N3 of purine for AAG-catalyzed excision (11) and is more suitable for
purines than for pyrimidines, eliminating the likelihood of repairing cytosine or thymine
adducts.
Here we also found 1,N2-EG to be a substrate for AAG, as was reported before (33, 41).
1,N2-eG is a promutagenic and genotoxic product formed from reactions with lipid
peroxidation byproducts and along with 1,N6-ethenoadenine, N2,3-ethenoguanine, and
3,N4-ethenocytosine, can result from exposure to industrial chemical pollutants such as
vinyl chloride or its metabolite chloroacetaldehyde. The fact that 1,N2-eG is repaired by
MUG (41) and AAG (Table 4-1 and Figure 4-6; refs. (4, 41, 49)) underscores the
importance of its repair for proper cellular homeostasis. Saparbaev et al. (41) found that
both the full-length and truncated A73AAG enzymes were able to bind to 1,N2-eG, but
only the full-length protein was able to release it from duplex DNA. A similar truncated
protein lacking the first 70 amino acid residues was slightly active in the repair but was
still much less active compared with the full-length protein (41). However, in the present
study, both the full-length and A80AAG excised 1,N2-eG equally well, albeit weakly
(Figure 4-6A and B, Table 4-1). Perhaps the possible conformational change brought
about by deletion of the N-terminal tail still allows the protein to bind and excise the
shorter 16-mer oligonucleotides (this study) but hinders excision in the longer
oligonucleotides (30-31-mer used by Saparbaev et al.(41)).
Finally, AAG is known to have an additional role in repairing deaminated bases such as
hypoxanthine and oxanine. Uracil arises as a deamination product of cytosine or it can be
misincorporated opposite of A from the dNTP pool during DNA synthesis, and is
promutagenic like all deaminated base lesions. Efficient repair of this lesion is
accomplished by base excision repair involving uracil DNA glycosylases (UDGs),
comprised of four families thus far (45, 50). In the present study, we have found that the
full-length AAG (and not A80AAG) can excise uracil to a limited extent with slow
excision kinetics, in single- or double-stranded DNA when paired with G (Figure 4-7A-C,
Table 4-1), similar to the deaminated bases hypoxanthine (Figure 4-5D-F, Table 4-1) and
oxanine (40). The inactivity shown by the truncated A80AAG may suggest that the N-
terminal tail is necessary in recognizing and excising uracil.
In conclusion, we report significant overlap in substrate specificity between AAG and
other repair enzymes such as AlkB, MUG, or UDG. As a genotoxic and mutagenic
lesion, IMeG was known to be a substrate repaired efficiently by the direct reversal
protein AlkB, and we now find that it is a good AAG substrate. It would seem
advantageous to the cell to have backup DNA repair systems to eliminate this lesion in
the event that one system is unavailable. Evaluation of the mutagenic and genotoxic
activities of IMeG in AAG-proficient and AAG-deficient cell lines is a priority based
upon this study. As a damaged lesion from the environment and from lipid peroxidation
byproducts, 1,N2-eG is also a shared substrate between MUG and AAG. Although both
truncated and full-length AAG showed similar glycosylase activity toward most
substrates in this study, it was shown by another study that the N-terminal domain was
essential in the excision of 1,N2-EG. However, we did find that the truncated and full-
length AAG protein showed completely different activity toward uracil, highlighting the
significance of the N-terminus in the glycosylase activity of AAG. Moreover, our results
of AAG activity on EA and Hx-containing single-stranded DNA may underscore the
significance of single-stranded DNA repair, in which other repair proteins such as
photolyase and AlkB are also involved.
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5. CHAPTER 5 -- Summary and Conclusions
5.1. Summary and Conclusions
In this thesis, we explored the repair of DNA damages by a set of direct reversal DNA
repair proteins, namely AlkB and two of its mammalian homologs (ABH2 and ABH3),
and any interaction and overlap with the base excision repair protein AAG, particularly in
response to pathology involving etheno base lesions. To approach this study, we first
examined whether expression of the AlkB and ABH proteins in E. coli and established
human cell lines could confer resistance upon alkylation damage. We demonstrated that
AlkB and ABH expression in AlkB-deficient E. coli strain enhance survival upon MMS
treatment. However, no phenotypic difference was observed in several human cell lines
with expressed AlkB/ABH when compared to wild-type cells. It is possible that the
protein levels are tightly regulated in order to minimize the generation of the toxic
formaldehyde byproduct from the repair reaction by AlkB, which must be further
processed by the cell. We also hypothesize that endogenous ABH proteins are likely
maintained at sufficient levels for repair of the small amounts of lmeA and 3meC
induced by MMS in double-stranded DNA due to their involvement in base-pairing.
Therefore, expressed ABH proteins may not be needed and eventually degraded. Also, it
is possible that the ABH proteins need to interact with each other for maximal function so
that singly expressed ABH proteins may not enhance the repair.
We next focused on mice deficient in Abh2 and/or Abh3 in order to investigate whether
using knockout cells would eliminate the possibility of sufficient repair by endogenous
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Abh proteins. This also allowed us to determine any interaction between the Abh2 and
Abh3 proteins. Following treatment of bone marrow cells ex vivo with MMS, we
observed that Abh2 - - or Abh2-Abh3 - bone marrow cells exhibited increased sensitivity
compared to WT or Abh3 - bone marrow cells. These results are consistent with a
previous finding in mouse embryonic fibroblasts (1), indicating a protective role of the
Abh2 protein upon MMS exposure in a knockout background.
Results thus far led us to further explore the role of the Abh2 and Abh3 proteins in a
knockout background. Using the Abh2/Abh3 knockout mice, we examined not only the
genetic interaction between Abh2 and Abh3, but also how they relate to the Aag DNA
glycosylase enzyme that can initiate BER at a variety of alkylated DNA bases. To this
end, we studied the response to chronic inflammation in mice deficient for Aag and/or
Abh2 and Abh3, because all three proteins repair etheno base lesions, common lesions
induced by chronic inflammation. Using the mouse model of AOM and DSS to mimic
episodic colitis, we found that either in the absence of Aag, or in the absence of both
Abh2 and Abh3, an increased sensitivity was observed including increased colon tumors
and more severe spleen and colon pathology.
The effects of Abh2 and Abh3 proteins appear to lead to differences in sensitivity in
different cell types. Unlike in the mouse embryonic fibroblasts (1) and bone marrow,
where the deficiency in Abh2 alone (but not Abh3 alone) leads to sensitivity against
MMS damage, the absence of Abh2 alone does not result in measurable sensitivities in
the spleen and colon, or tumor formation in response to chronic inflammation, in the
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presence or absence of Aag. Only sensitivity from a combined effect of Abh2 and Abh3
together was observed, indicating that absence of Abh2 alone does not significantly alter
the response to chronic inflammation. Although it is necessary to determine whether
Abh3 - single knockout mice exhibit increased sensitivity, it is possible that either Abh2
does not contribute to repair or it needs to work in a complex with Abh3 together for
maximal activity in fighting the DNA damage induced by inflammation. We found that
in the response to chronic inflammation, base excision repair initiated by Aag remains as
the more dominant pathway in alleviating the effects of the inflammation-induced DNA
damage as deficiency in Aag tends to mask any possible sensitivity from the absence of
Abh2 or Abh3.
To further examine the genetic interaction of Aag, Abh2, and Abh3 in vivo, it will be
necessary to examine the response of the Abh3 -'- single mutant and Aag-Abh2-Abh3'
triple mutant to DSS-induced chronic colonic inflammation in order to determine whether
individual effects of Abh3 are detectable in the presence of Aag. The triple mutant would
aid in determining whether the single effect of Aag plus the combined effect of Abh2 and
Abh3 would greatly sensitize the mice. Moreover, molecular analysis measuring the
levels of accumulated base lesions, such as FA, EC, and 8oxoG, in the AOM + DSS-
induced chronic inflammation model in the different genotypes would confirm whether
sensitivities and tumorigenesis were indeed caused by unrepaired RONS-induced DNA
damage in the repair-deficient animals, as we have shown in Aag- mice (2). This would
be particularly informative for Abh2-Abh3 -, Aag-, Aag--Abh2 --, and Aag-Abh3 -, in
which increased tumorigenesis was significant. It would also be interesting to determine
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which lesions increased in these mice, and whether the lesion accumulations correlate to
the substrate preference by Aag versus Abh2/3.
To further understand the overlap in repair activity between AlkB and AAG, we
examined the kinetics of AAG activity on an extensive library of lesion-containing DNA
oligonucleotides. From these experiments, we observed multiple novel findings,
including a new substrate shared between AlkB and AAG, namely 1-methylguanine.
This strengthens the overlap in substrates repaired by these two proteins, in addition to
the already known substrates EA, EA (repaired robustly by AlkB), and 1,N2-G (repaired
weakly by AlkB).
To follow up on these findings, it would be interesting to examine any possible physical
interactions between AlkB and AAG. Because AAG was found to bind to a wide range
of substrates but only to excise a few, it would be interesting to examine whether AAG
can serve as an inhibitor in the repair reaction by AlkB on substrates that are tightly
bound by AAG but not repaired. Indeed, Fu and Samson have unpublished data
indicating that this is the case. Similarly, we can test whether AlkB can inhibit repair of
the shared substrates by AAG in reaction conditions optimized for AAG. In order to
assess whether these proteins compete for the same binding site on DNA, DNA
footprinting assays could also be performed. Furthermore, competition studies with both
AlkB and AAG acting on their shared substrates may allow us to determine which protein
is preferred for repair.
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In addition to studying inflammation in colon induced by a chemical irritant, we could
examine other mouse models of chronic inflammation. For example, one such approach
is to use a model involving mice deficient in interleukin-10 (IL-10). IL-10 inhibits
production of pro-inflammatory cytokines and its deficiency can lead to spontaneous
colitis (3) in response to gut flora (4). Thus, examining the effects of colitis on double or
triple mutants of IL-10 -, Abh2- , Abh3- , and Aag- mice would allow us to determine
whether Aag and/or Abh2/3 proteins can also suppress colon tumorigenesis and the
sensitive phenotype from colitis not induced chemically.
Other than models of inflammation in the colon, we can examine chronic inflammation in
different tissues to determine whether this protective effect of Aag and/or Abh2/3
proteins is a global effect. For example, chronic inflammation of the liver (hepatitis) is
associated with the development of hepatocellular carcinoma (HCC). One established
mouse model of inflammation-associated HCC model is the Mdr2-- mice. These mice
are deficient in the liver-specific P-glycoprotein that transports phosphatidylcholine
across the bile canalicular membrane, giving rise to accumulation of bile acids and portal
inflammation (5-7). Liver inflammation leads to hepatocyte dysplasia and a high
incidence of liver tumors in Mdr2 - mice as early as 16 months (5). Studying mutants of
Mdr2 - with Aag - and/or Abh - will allow us to determine whether these repair proteins
also have protective roles in another model of inflammation.
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